

CURRICULUM VITAE

NAME William F. Mieler, MD

BUSINESS ADDRESS Professor and Vice-Chairman
Department of Ophthalmology and Visual Science
University of Illinois at Chicago
1855 West Taylor Street
Chicago, IL 60612
Telephone (312) 996-7832
(312) 996-6590
FAX (312) 997-1474
E mail wmieler@uic.edu

CITIZENSHIP U.S. Citizen

EDUCATION

1975 B.S.- Chemistry University of Wisconsin-Madison
Phi Kappa Phi – 1975

1979 M.D. University of Wisconsin-Madison, Medical School
Alpha Omega Alpha - 1978

INTERNSHIP 6/79-6/80 Flexible, Mercy Hospital and Medical Center,
San Diego, CA

RESIDENCY 7/80-7/83 Ophthalmology, Bascom Palmer Eye Institute,
University of Miami, Miami, FL

FELLOWSHIP 7/83-7/84 Retina-Vitreous, The Eye Institute,
Milwaukee County Medical Complex,
Medical College of Wisconsin, Milwaukee, WI

CHIEF RESIDENT 7/84-6/85 Ophthalmology, Bascom Palmer Eye Institute,
CLINICAL INSTRUCTOR University of Miami, Miami, FL

FELLOWSHIP 7/85-1/86 Ocular Oncology, Wills Eye Hospital,
Thomas Jefferson University,
Philadelphia, PA

CERTIFICATION AND LICENSURE

7/80 Florida Medical License (ME0037139)
7/80 National Board of Medical Examiners
7/84 Wisconsin Medical License (25363)
10/84 American Board of Ophthalmology
6/85 Pennsylvania Medical License (MT-O1448O-T)
10/99 Texas State Medical License (L5191)
4/04 Illinois Medical License (036-111243)

ACADEMIC APPOINTMENTS

07/84-06/85 Clinical Instructor - Chief Resident, Bascom Palmer Eye
Institute, University of Miami, Miami, FL

07/85-06/89 Assistant Professor of Ophthalmology, The Eye Institute,
Medical College of Wisconsin, Milwaukee, WI
07/85-07/99 Co-Director Ocular Oncology, The Eye Institute,
Medical College of Wisconsin, Milwaukee, WI
07/89-06/93 Associate Professor of Ophthalmology, The Eye Institute,
Medical College of Wisconsin, Milwaukee, WI
01/86-07/99 Staff Physician, Veterans Administration Hospital,
Milwaukee, WI
06/89-07/99 Staff Physician, Children's Hospital of Wisconsin, Medical
College of Wisconsin, Milwaukee, WI
07/92-07/99 Chief, Vitreoretinal Service, The Eye Institute
12/92-07/99 Courtesy Staff, St. Joseph's Hospital, Milwaukee, WI
07/93-07/99 Professor of Ophthalmology, The Eye Institute, Medical
College of Wisconsin, Milwaukee, WI
01/98-07/99 The Jack A. and Elaine D. Klieger Chair in Ophthalmology,
The Eye Institute, Medical College of Wisconsin,
Milwaukee, WI
07/99-04/04 Professor of Ophthalmology, Cullen Eye Institute, Baylor
College of Medicine, Houston, TX
07/99-04/04 Staff Physician, Veterans Administration Hospital, Houston,
TX
08/99-04/04 Staff Physician, MD Anderson Cancer Hospital, University
of Houston, Houston, TX
08/99-04/04 Staff Physician, St. Luke's Hospital, Houston, TX
04/04-06/08 Professor and Chairman, Department of Ophthalmology
and Visual Science, University of Chicago, Chicago, IL
11/07-06/08 Residency Program Director, University of Chicago
08/08-present Professor and Vice-Chairman, Department of
Ophthalmology and Visual Science, University of Illinois
at Chicago (UIC)

SOCIETY MEMBERSHIPS

American Academy of Ophthalmology, 1982-present
Honor Award, 1992
Lifelong Education for the Ophthalmologist Continuing Education Recognition
Award, 2000
AAO Council, 2000-present
Senior Honor Award, 2001
Representative to the American College of Surgeons, 2007-present
Association for Research in Vision and Ophthalmology, 1986-present
Miami Ophthalmological Society, 1980-1985
Aspen Retinal Detachment Society 1986-present
Milwaukee Ophthalmological Society, 1986-1999
National Eye Trauma System, Trauma Center Director, The Eye Institute, 1986-1999
Wisconsin-Upper Michigan Ophthalmological Society, 1986-present
Fluorescein Club (Novotny Society), 1985-present
American Academy of Ophthalmology Fluorescein Club (Gass Club), 1992-present
Retina Study Club of Chicago, 1987-present
Bascom Palmer Eye Institute Alumni Association, 1983-present
Wisconsin Academy of Ophthalmology, 1987-1999
Eye Institute Alumni Association, 1986-present

Wisconsin Medical Alumni Association, 1980-present
The Cancer Center, Medical College of Wisconsin, 1987-1999
Vitreous Society, Member, 1988-present
 Honor Award, 1997
 Senior Honor Award, 2001
American Society of Retina Specialists (previously the Vitreous Society), 2002-present
 Chairperson, Members-In-Training Committee, 2002-03
 Board of Directors, 2002-03
 Crystal Apple Award, 2005 (Excellence in Teaching)
Pan-American Association, Member, 1988-present
 Board of Directors, USA representative, 2001-03, 2003-05, 2005-07
 Representative to the American Academy of Ophthalmology Council, 2006-08
 Chair, Foundation Grants Committee, 2006-present
Macula Society, Member 1988-present
 Program Chairman 1993-1995
 Executive Committee 1993-present
 Treasurer, 1996-97
 Secretary 1998-99
 President-Elect 2000-02
 President, 2002-04
 Member, Meeting Planning Committee, 2000-present
 Member, Program Committee, 2000-present
 Representative to the AAO Council, 2000-02, 2003-05
 Nominating Committee of the Subspecialty/Specialized Interest Section
 of the Council, 2002-present
 Representative to the Pre-American Academy of Ophthalmology (AAO)
 Vitreoretinal Symposium Planning Committee, 2000-04
 Vice-Chairman, Vitreoretinal Symposium Planning Committee, 2003
 Chair, Vitreoretinal Symposium Planning Committee, 2004
 Media Spokesperson, 2001-04
 Awards Committee, 2002-04
 By-Laws Committee, 2002-04
 Nominating Committee, 2002-04
 Research Committee, 2002-04
 Credentials Committee, 2002-04
Retina Society, 1989-present
 Executive Committee 1994-1997
 Retina Society Travel Grant Award Committee 1997-present
 Chair, Retina Society Fellow Grant Award Committee, 2005-present
 Congressional Advocacy representative, 2007-present
Fellow of the American College of Surgeons, 1989-present
 Board of Directors (alternate), representing the American Ophthalmological
 Society, 2005-present
Fellow of the American College of Surgeons, Wisconsin Chapter, 1989-99
Fellow of the American College of Surgeons, Texas Chapter 1999-2004
Fellow of the American College of Surgeons, Illinois Chapter 2004-present
International Society of Ocular Trauma (ISOT), 1992-present
Walter Zeit Fellow, Medical College of Wisconsin, 1992-present
American Uveitis Society
 Member, 1994-present
Club Jules Gonin (International Retinal Society)
 Member 1996-present

American Medical Association
Member 1996-present
American Ophthalmological Society
Associate Member, 1997-1998
Member, 1998-present
American College of Surgeons, Board of Directors (alternate), 2005-present
Texas Ophthalmological Association
Member, 2000-04
Wills Eye Hospital Society
Member, 2000-present
Baylor Ophthalmology Alumni Association
Member, 2000-present
Eye Tumor Research Advocacy Group (ETRAG)
Member, 2000-present
Houston Ophthalmological Society
Member, 2001-04
International Ocular Inflammation Society (IOIS)
Member 2002-present
Southwest Oncology Group
Member, 2003-present
Association of University Professors in Ophthalmology (AUPO)
Member, 2004-present
Rabb Retina Study Club
Member, 2004-present
European Society of Retinal Specialists (EURETINA)
Member, 2007-present
American Society of Cataract and Refractive Surgery (ASCRS)
Retina Clinical Committee, 2008-present

HOSPITAL COMMITTEES AND ADMINISTRATIVE APPOINTMENTS

Bascom Palmer Eye Institute and Anne Bates Leach Eye Hospital (con't)
Quality Assurance Committee, 1981-1985
Operating Room Committee, 1984-1985
Outpatient Committee, 1984-1985
Resident Selection Committee, 1982-1984
Utilization Review Committee, 1984-1985
The Eye Institute, Medical College of Wisconsin
Institutions Research Committee, 1988-1992
Marketing Committee 1994-1999
Practice Development 1994-1999
Baylor Eye Care Alliance (BECA)
Member, Board of Directors, 1999-2004
Baylor College of Medicine, Cullen Eye Institute
Member, Continuing Education Committee, 2000-04
Faculty Appointments and Promotions Committee, 2000-02
Continuing Education Committee, 2001-02
Neurosensory Eye Surgery Equipment Committee, 2002-present
Illinois Association of Ophthalmology, 2004-present
University of Chicago, 2004-present
Board of Trustees, University of Chicago Practice Plan

Divisional Executive Committee
Clinical Chairs Committee
Clinical Operations Subcommittee
Physicians Fundraising Working Group
Executive Committee of the Medical Staff
Office of the Medical Center Compliance
Operative Services Executive Committee
Biological Sciences Division (BSD) Development Long-Term Planning
Committee
Program Planning Committee, Chair, 2005-06
U Chicago Medical Center, Budget Oversight Committee, 2007-08

GRANTS AND CONTRACTS

Collaborative Ocular Melanoma Study (National Eye Institute), Principle Investigator, Medical College of Wisconsin, 1986-99, \$184,000
Silicone Oil Study (National Eye Institute), Co-investigator, Medical College of Wisconsin, 1987-92, \$41,000, Principle investigator, 1992-95
Extended Follow-up Silicone Oil Study (National Eye Institute), EY0771, Principle Investigator, Medical College of Wisconsin, 10/92-6/94, \$8,050
Macular Photocoagulation Study (National Eye Institute), Co-investigator, Medical College of Wisconsin, 1988-present, \$500,000
Endoexcimer Laser Intraocular Photodecomposition of Choroidal Melanoma in a Rabbit Model, Cancer Center, Principle investigator, Medical College of Wisconsin, 1987, \$7,230
Endo-Irradiation of Choroidal Melanoma in a Rabbit Model, Cancer Center, Principle investigator, Medical College of Wisconsin, 1989-1990, \$8,250
Eye Disease Case Control Study (National Eye Institute), Co-investigator, Medical College of Wisconsin, 1988-99, \$76,551
Simultaneous Ferromagnetic Hyperthermia and I-125 Brachytherapy in the Treatment of Choroidal Melanoma (National Cancer Institute), Co-investigator, Medical College of Wisconsin
Endophthalmitis Vitrectomy Study (National Eye Institute), Co-investigator, Medical College of Wisconsin, 1989-93, \$84,896
Richard James Silicone Oil Study, Co-investigator and Study Surgeon, Medical College of Wisconsin, 1990-95, unfunded
Pefluroron TM for Ophthalmic Surgery, Co-investigator and Study Surgeon, Medical College of Wisconsin, 1992-96, unfunded
Vitreotomy for Treatment of Macular Holes, Co-investigator, Medical College of Wisconsin, 1992-95
Core Grant for Vision Research, Collaborating Investigator, Medical College of Wisconsin, National Institute of Health (NIH) P30 Ey01931, 4/92 to 3/97, \$777,692.
Dose-Ranging and Efficacy Study, Comparing Interferon Alfa-2a Treatment (1.5 MIU vs 3 MIU vs 6 MIU) with Placebo, each T.I.W. for One Year, in Patients with Neovascular Age-Related Macular Degeneration (AMD) with Foveal Involvement (Hoffmann-LaRoche), Co-Principle investigator, Medical College of Wisconsin, 1994-99, \$124,000
Virulence Factors in *Bacillus cereus* Endophthalmitis (National Institutes of Health), Co-investigator, Medical College of Wisconsin, 1995-99, \$299,690
Small Ocular Melanoma Treatment Trial, Co-Investigator, Medical College of Wisconsin, 1996-present, \$534,413 (National Cancer Institute)

- Phase III Safety and Efficacy Study of Vitrase (Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage (Advanced Corneal Systems), Principal Investigator, 1998-99 (Medical College of Wisconsin), Co-Investigator 1999-present (Baylor College of Medicine)
- Protein Kinase C b Inhibitor-Diabetic Macular Edema Study (PKC-DMES) Protocol B7A-MC-MBBK (Lilly, Inc), Principle investigator, Medical College of Wisconsin, 1998-99
- Phase III randomized, multicenter, double-masked, placebo-controlled parallel group study of Tin Ethyl Etiopurpurin (SnET2)) photodynamic therapy in the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration, Co-investigator, Medical College of Wisconsin, Miravant Pharmaceuticals, Inc., 1998-99
- Pharmacologic Vitreolysis, Knights Templar Eye Foundation Grant, Co-investigator, Baylor College of Medicine, 2000-04, \$30,000
- An Open-Label, Multicenter, Safety Study of the Treatment of Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) using Photodynamic Therapy with Verteporfin for Injection, Co-investigator, Baylor College of Medicine, 1999-2000, unfunded
- Vitreous Penetration of Orally Administered Gatifloxacin in Humans. Co-investigator, Baylor College of Medicine, 2000-01, \$19000
- Early Treatment for Retinopathy of Prematurity Study, National Eye Institute, Co-Investigator, Baylor College of Medicine, 2000-04.
- Pilot Study for Intravitreal Injection of Triamcinolone Acetonide in Exudative Age-Related Macular Degeneration, Co-investigator, Baylor College of Medicine, 2001-03, unfunded
- The Visudyne Patient Registry System. Novartis Pharmaceuticals, Inc., Principle Investigator, Baylor College of Medicine 2001-04), Principle Investigator, University of Chicago, 2004-06.
- A Phase II/III randomized, double-masked, controlled, dose-ranging, multi-centered comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (Anti-VEGF Pegylated Aptamer) given every 6 weeks for 54 weeks, in patients with exudative Age-Related Macular Degeneration (AMD). EyeTech Pharmaceuticals, Principle Investigator, Baylor College of Medicine, 2001-04, \$159,659
- A Phase 2 Randomized, Multicenter, Dose-Ranging, Controlled, Parallel-Group Trial To Assess the Safety and Efficacy of Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in the Treatment of Diabetic Macular Edema, Oculex Pharmaceuticals, Inc., Principle Investigator, Baylor College of Medicine, 2001-02, \$77,780
- Adjunctive diclofenac after Visudyne PDT (ADD-V). CBPD952A2201. A 3 month Randomized, Controlled, Double-Masked, Multicenter, Phase II Study of the Effects of Adjunctive diclofenac therapy and Visudyne PDT in patients with predominantly classic subfoveal CNV (choroidal neovascularization) secondary to Age-Related Macular Degeneration, Principle Investigator, Baylor College of Medicine, 2002-03, \$42,160.
- Photodynamic Therapy and Intravitreal injection of Triamcinolone Acetonide in Exudative Age-Related Macular Degeneration. Co-investigator, Baylor College of Medicine, 2001-03, unfunded
- An Open-Label, Phase I, Single Administration, Dose Escalation Study of AD (GV) PEDF.11D in Neovascular Age-Related Macular Degeneration (AMD). GenVec, Inc., Co-investigator, Baylor College of Medicine, 2002-present, \$10162/patient

- A Randomized, Placebo-Controlled, Double-Masked, Multicenter Phase III Study of the effect of Visudyne therapy in occult with no classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD): Visudyne in Occult (VIO), Novartis, Inc., Principle Investigator, Baylor College of Medicine, 2002-04, \$197278 (\$14091/patient).
- A Phase I/II, Single-masked, Multicenter study of safety, tolerability, and efficacy of multiple dose intravitreal injections of RhuFab V2 in combination with verteporfin (Visudyne) photodynamic therapy in subjects with neovascular age-related macular degeneration. Principle Investigator, Genentech, Baylor College of Medicine, 2002-04.
- Evaluation of the Effects of Ad PEDF.11D in Neovascular Age-Related Macular Degeneration (AMD) using Optical Coherence Tomography (OCT). GenVec, Co-investigator, Baylor College of Medicine, 2002-04, \$12,000.
- A Phase II Randomized, Controlled, Double-Masked, Dose-Finding, Multi-Center Comparative Trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (Anti-VEGF Pegylated Aptamer), given every 6 weeks for 12 to 30 weeks to patient with clinically significant diabetic macular edema (CSME) involving the center of the macula. EyeTech Pharmaceuticals. Co-investigator, Baylor College of Medicine, 2002.
- An Open-Label, Multi-Center Trial of the safety, tolerability and pharmacokinetics of intravitreal injections of pegaptanib sodium (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration, EyeTech Pharmaceuticals, Baylor College of Medicine, Co-Investigator, 2002-04.
- ADV/TK-Mediated Gene Therapy for Retinoblastoma. National Institute of Health, Co-Investigator, Baylor College of Medicine, 2003-04
- A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection Controlled Study of the Efficacy and Safety of Rhufab V2 in Subjects with Minimally Classic or Occult Subfoveal Neovascular Related Macular Degeneration (MARINA study), Principle Investigator, Baylor College of Medicine, 2003-04.
- EOP1005: A Phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant diabetic macular edema (CSME) involving the center of the macula. Co-investigator, University of Chicago, 2004-present.
- EOP1011: A Phase II randomized, double-masked multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreal injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO. Co-investigator, University of Chicago, 2004-present.
- SCORE study. A randomized trial to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema associated with central retinal vein occlusion and branch retinal vein occlusion. Co-investigator, University of Chicago, 2004-present.
- INSPIRE. Protocol 06-102. A randomized, double-masked, placebo, controlled, parallel group, multi-center, dose-ranging study of denufosol tetrasodium (INS37217) intravitreal injection in subjects with rhegmatogenous retinal detachment. Co-investigator, University of Chicago, 2004-05. Principle investigator, 2005-present.
- Allergan (Posurdex). A six-month, phase 3, randomized, sham-controlled trial (with six-month open-label extension) to assess the safety and efficacy of 700 ug

- and 350 ug dexamethasone posterior segment drug delivery system (DEX PS DDS applicator system) in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion. Co-investigator, University of Chicago, 2004-present.
- Alcon C-02-60. An evaluation of efficacy and safety of posterior juxtascleral administration of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients at risk for developing sight-threatening choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). Co-investigator, University of Chicago, 2004-present.
- Diabetic Retinopathy Clinical Research (DRCR) network. Co-investigator, University of Chicago, 2003-present.
- VisIT (Visudyne and Intravitreal Corticosteroids). Novartis Pharmaceuticals, Inc., Treatment of choroidal neovascularization secondary to age-related macular degeneration. Novartis Pharmaceutical, Inc. Principle Investigator, University of Chicago, 2004-study pending.
- An Open-Label, Multi-Center Trial of the safety, tolerability and pharmacokinetics of intravitreal injections of pegaptanib sodium (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration, EyeTech Pharmaceuticals, Baylor College of Medicine, Co-Investigator, 2002-04
- A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection Controlled Study of the Efficacy and Safety of Rhufab V2 in Subjects with Minimally Classic or Occult Subfoveal Neovascular Related Macular Degeneration (MARINA study), Principle Investigator, Baylor College of Medicine, 2003-04
- The Macula Foundation, Assessment of Retinal Blood Flow in Diabetic Rodents after Anti-VEGF Therapy using Scanning Laser Ophthalmoscopy. Co-principle investigator, U Chicago and IIT, 2006-07
- Center for Integrative Neuroscience and Neuroengineering Research (CINNR), Investigation of a dual angiogenic and neuronal role of vascular endothelial growth factor (VEGF) in the visual system. Co-principle investigator, IIT and U Chicago, 2006-07
- The Lincy Foundation Research Grant, A Novel Anti-Angiogenic Drug Delivery System for Treatment of Age-Related Macular Degeneration (AMD) via Thermo-Responsive Hydrogels. Co-principle investigator, U Chicago and IIT, 2006-08.
- The Macula Foundation, Investigation of Retinal Angiogenesis Inhibition by Methylnaltrexone. Co-principle investigator, U Chicago and IIT, 2007-08.
- Allergan (DME) AGN206207-011-01, A 3-year, phase 3, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 ug and 350 ug Dexamethasone posterior segment drug delivery system (DEX PS DDS Applicator System) in the treatment of patients with diabetic macular edema. Co-investigator, U Chicago, 2006-present
- Alimara (FAME) A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5 micrograms/day and ASI-001B 0.2 micrograms/day Fluocinolone acetonide intravitreal inserts to sham injection in subjects with diabetic macular edema. Co-investigator, 2005-present.
- Regeneron (CLEAR-IT AMD)-2) A randomized controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap in patients with neovascular age-related macular degeneration, clinical

- evaluation of anti-angiogenesis in the retina intravitreal trial AMD Phase 2 (CLEAR-IT AMD-2) protocol. Co-investigator, U Chicago, 2006-present.
- Alcon (Nevanac) Determination of aqueous and vitreous concentration of topically administered Nepafenac 0.1% (Nevanac) and Ketorolac 0.4% (Acular LS) in humans (protocol no. CMS-06-07). Co-investigator, U Chicago, 2006-07
- Regeneron (VEGF Trap) An exploratory study of the safety, tolerability and biological effect of intravitreal administration of VEGF Trap in patients with neovascular age-related macular degeneration (VEGF-OD-0502). Co-investigator, U Chicago, 2005-07
- Othella (OT-551-002) A multi-center, double-masked, randomized, vehicle-controlled, parallel group evaluation of the safety and efficacy of OT-551 ophthalmic solution to prevent formation or delay progression of nuclear cataract formation in post-vitrectomy patients. Principle investigator, U Chicago, 2005-07.
- Acuity (ACU201) A phase II, randomized, double-masked, controlled, dose comparisons study of Cand5 for intravitreal injection for the treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration. Principle investigator, U Chicago, 2005-07
- Genentech (SAILOR) A phase IIIb, multi-center study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Protocol FVF3689). Principle investigator, U Chicago, 2006-07
- Novartis (PTK787) A randomized, double-masked, multicenter, phase I/II study of the safety of PTK787 administered in conjunction with photodynamic therapy with Visudyne to patients with predominantly classic, minimally classic, or occult with no classic subfoveal choroidal neovascularization secondary to age-related macular degeneration. Principle investigator, U Chicago, 2006-07.
- NEI (AREDS2) The Age-Related Eye Disease Study 2 (AREDS2): A multi-center, randomized trial of lutein, zeaxanthin, and omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA] in age-related macular degeneration. Principle investigator, U Chicago, 2006-present.
- MacTel (15026A) A natural history study of macular telangiectasia The MacTel Study. Principle investigator, U Chicago, 2006-07.
- Eyetech (LEVEL Study) A phase IV, open label, multi-center, trial of maintenance intravitreal injection of Macugen (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement. Principle investigator, U Chicago, 2007-present.
- Genentech (DME) An open-label, phase I/II, prospective, triple-arm, randomized, unmasked, pilot study of the activity, efficacy and tolerability of ranibizumab 0.5 mg intravitreal injection for the treatment of diabetic macular edema (DME) in subjects following elective cataract surgery. Principle investigator, U Chicago 2006-present.
- Genentech (NVG) An open-label, phase I/II, randomized, prospective, double-arm unmasked pilot study of the activity, efficacy and tolerability of ranibizumab 0.3 mg intravitreal injection as compared to ranibizumab 0.5 mg intravitreal injection for the treatment of neovascularization of the iris and neovascular glaucoma. Co-investigator, U Chicago, 2006-present.
- Genentech (DME, FVF 4168g/4170g) A phase III, double-masked, multi-center,

- randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus. Co-investigator, U Chicago, 2007-present.
- Novartis (DENALI) A 24 month, randomized, double-masked, controlled, multi-center, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne) photodynamic therapy administration in conjunction with ranibizumab (Lucentis) versus ranibizumab (Lucentis monotherapy) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Principle investigator, 2007-present.
- NeoVista (CABERNET), Principle Investigator, U Chicago, 2007-08
- Occulogix (RHEO-AMD-01) Safety and effectiveness in a multi-center, randomized, sham-controlled, investigation for age-related macular degeneration (AMD) using rheopheresis treatment. Principle investigator, U Chicago, 2007-08

OTHER PROFESSIONAL ACTIVITIES

- National Eye Trauma System, Trauma Center Director, The Eye Institute, 1986-1999
- National Eye Trauma System Committee for Eye Trauma Centers Standards, 1988-present
- National Eye Trauma System Research Committee, 1988-present
- Course Director, Third National Eye Trauma Symposium, Milwaukee, WI, July 1988.
- Guest Editor, RETINA, 1990 (Supplement), The Third National Eye Trauma Symposium.
- Collaborative Ocular Melanoma Study (COMS)
- Member of the Executive Committee, 1986-1988
 - Member of the Quality Assurance Committee, 1986-present
 - Site Visit (COMS) Wilmer Eye Institute, Johns Hopkins Medical Center, Baltimore, MD, November 1986
 - Site Visit (COMS) Cornell University, New York Hospital, New York, NY, January 1987
 - Site Visit (COMS) Texas Retina Associates, Dallas, TX, February 1987
 - Site Visit (COMS) University of Wisconsin, Madison, WI, July 1987
 - Surgical Certification Committee, 1988-present
 - Site Visit (COMS) Photography Reading Center, Iowa City Iowa, January 1990
 - Small Tumor Substudy, Member 1995-present
- Reviewer, Veteran's Administration Medical Research Grant Proposals, 1990-present
- Audio Journal Ophthalmology Review tape: Posterior Segment Trauma, 1989
- American Academy of Ophthalmology Instruction Courses
- Mieler WF, Williams GA: Systemic Therapeutic Agents and Retinal Toxicity, 1987-1989
 - Mieler WF: Therapeutic Options in the Management of Choroidal Melanoma, 1988
 - Williams GA, McDonald HR, Neuwirth J, Mieler WF: Avoidance and Management of Posterior Segment Complications of Cataract Surgery, 1988
 - Liggett PE, Ryan SJ, Parver LM, Sternberg P, deBustros SN, Mieler WF: NETS: Management of Penetrating Ocular Injuries, 1989-1992
 - Mieler WF, Liggett PE: Therapeutic Options in the Management of Choroidal Melanoma, 1989-1990

- Mieler WF, Williams GA, Sneed SR, Williams DF: Systemic Therapeutic Agents and Retinal Toxicity, 1991-1993, 1994-1996
- Mieler WF, Liggett PE: Therapeutic Options in the Management of Uveal Melanoma, 1992-1994
- Morris RE, Kuhn F, Mieler WF, Cole H: Management of Intraocular and Orbital Foreign Bodies, 1993, 1994-1996
- Mieler WF, Han DP, Pulido JS: Update on Vitreoretinal Surgery, 1993-1995.
- Mieler WF, Han DP, Pulido JS, Connor TB: Update on Vitreoretinal Surgery, 1996-1998.
- Mieler WF, Jampol LM, Yannuzzi L, Shields JA: Mystery Retina: Interactive Discussion of Challenging Cases, 1996-1998.
- Mieler WF, Sneed SR, Williams DF: Systemic Therapeutic Agents and Retinal Toxicity, 1997-98
- Bressler NM, Singerman LA, Brucker SA, Mieler WF: Macula Society Update, 1997-98
- Mieler WF, Williams GA, Sneed SR, Williams DF: Systemic Therapeutic Agents and Retinal Toxicity, 1999-2000
- Mieler WF, Jampol LM, Yannuzzi L, Shields JA: Mystery Retina: Interactive Discussion of Challenging Cases, 1999-2000
- Mieler WF, Mitra RA, Kuhn F: Controversies in the Management of Open-Globe Injuries, 1999-2000
- Mieler WF, Han DP, Connor TB, Kim JE, Holz ER: Update on Vitreoretinal Surgery, 1999-2000
- Bressler NM, Singerman LA, Brucker SA, Mieler WF, Sternberg P: Update from the Macula Society: Impact of Randomized Clinical Trial Results for Age-Related Macular Degeneration, 1999-2000
- Mieler WF, Han DP, Connor TB, Heuer DK, Sheth BP, Damasceno E: Update on the Management of Diabetic Retinopathy, 1999
- Holz ER, Mieler WF, Gross RL, Hamill MB: Multidisciplinary Surgical Approach to Complex Surgical Disorders, 2000-01.
- Han DP, Dev S, Mieler WF: Posterior Segment Complications of Anterior Segment Surgery, 2001-02
- Mieler WF, Connor TB, Han DP, Holz ER, Kim JE: Advances in Vitreoretinal Surgery 2001.
- Mieler WF, Jampol LM, Shields JA, Yannuzzi LA, Slakter JS: Mystery Retina: Interactive Discussion of Challenging Cases, 2001-02
- Mieler WF, Holz ER, Kuhl DR, Schwartz SG: Controversies in the Management of Rhegmatogenous Retinal Detachment, 2001-02
- Mieler WF, Kuhn FP, Mitra RA: Controversies in the Management of Open-Globe Injuries, 2001-02
- Mieler WF, Sneed SR, Williams DF, Williams GA: Systemic Therapeutic Agents and Retinal Toxicity, 2001-02
- Singerman LA, Brucker SA, Mieler WF, Sternberg P, Ferris R: Update from the Macula Society: Impact of Randomized Clinical Trial Results for Age-Related Macular Degeneration, 2001-02
- Gombos D, Kim SK, Mieler WF: Diagnostic Challenges in the Cancer Patient, 2002-04
- Mieler WF, Sneed SR, Williams DF, Williams GA: Systemic Therapeutic Agents and Retinal Toxicity, 2003
- Mieler WF, Jampol LM, Shields JA, Yannuzzi L: Mystery Retina: Interactive Discussion of Challenging Cases, 2003
- Mieler WF, Holz ER, Schwartz SG, Kuhl DP, Lincoff HA, Kreissig I:

- Therapeutic Options in the Management of Rhegmatogenous Retinal Detachment, 2003
- Mieler WF, Schwartz SG, Kuhl DP, Benz MS, Lincoff HA, Kreissig I: Therapeutic Options in the Management of Rhegmatogenous Retinal Detachment, 2004
- Mieler WF, Jampol LM, Shields JA, Yannuzzi L, Spaide RF: Mystery Retina: Interactive Discussion of Challenging Cases, 2004
- Mieler WF, Sneed SR, Williams GA: Systemic Therapeutic Agents and Retinal Toxicity, 2004
- Han DP, Dev S, Mieler WF, Heier J: Posterior Segment Complications of Anterior Segment Surgery, 2004
- Finger PF, Harbour W, Mieler WF, Singh A: Imaging of Intraocular, Adnexal, and Orbital Tumors, 2004
- Mieler WF, Sneed SR, Williams DF, Williams GA, Kim SK: Systemic Therapeutic Agents and Retinal Toxicity, 2005
- Mieler WF, Schwartz SG, Kuhl DP, Holz ER, Lincoff HA, Kreissig I: Therapeutic Options in the Management of Rhegmatogenous Retinal Detachment, 2005
- Mieler WF, Jampol LM, Shields JA, Spaide RF: Mystery Retina: Interactive Discussion of Challenging Cases, 2005
- Mieler WF, Sneed SR, Williams DF, Williams GA, Kim SK: Systemic Therapeutic Agents and Retinal Toxicity, 2006
- Hariprasad SM, Mieler WF, Flynn HW, Das TP: Advances in Endophthalmitis Management, 2006
- Mieler WF, Schwartz SG, Kuhl DP, Holz ER, Lincoff HA, Kreissig I: Therapeutic Options in the Management of Rhegmatogenous Retinal Detachment, 2006
- Mieler WF, Jampol LM, Shields JA, Yannuzzi L, Spaide RF: Mystery Retina: Interactive Discussion of Challenging Cases, 2006
- Apte R, Hariprasad SM, Mieler WF, Blumenkranz MS: Intravitreal Pharmacology, 2007
- Mieler WF, Sneed SR, Williams DF, Williams GA: Systemic Therapeutic Agents and Retinal Toxicity, 2007
- Mieler WF, Schwartz SG, Kuhl DP, Holz ER, Lincoff HA, Kreissig I: Therapeutic Options in the Management of Rhegmatogenous Retinal Detachment, 2007
- Mieler WF, Jampol LM, Shields JA, Yannuzzi L, Spaide RF: Mystery Retina: Interactive Discussion of Challenging Cases, 2007
- Mieler WF, Kang Derwent JJ: Advances in Drug Delivery to the Posterior Segment, 2007
- Finger PF, Mieler WF, Singh A: Imaging of Intraocular, Adnexal, and Orbital Tumors for the Clinician, 2007
- Mieler WF, Kuhn F, Mitra RA: Controversies in the Management of Open-Globe Injuries involving the Posterior Segment, 2007
- Hariprasad SM, Mieler WF, Flynn HW, Das TP: Advances in Endophthalmitis Management, 2007
- Apte R, Hariprasad SM, Mieler WF, Sternberg P: Intravitreal Pharmacology, 2007
- Mieler WF, Kuhn F, Mitra RA: Controversies in the Management of Open-Globe Injuries involving the Posterior Segment, 2008
- Hariprasad SM, Mieler WF, Flynn HW, Das TP: Advances in Endophthalmitis Management, 2008

- Mieler WF, Sneed SR, Williams DF, Williams GA: Systemic Therapeutic Agents and Retinal Toxicity, 2008
Mieler WF, Schwartz SG, Kuhl DP, Holz ER, Lincoff HA, Kreissig I: Therapeutic Options in the Management of Rhegmatogenous Retinal Detachment, 2008
Mieler WF, Jampol LM, Shields JA, Yannuzzi L, Spaide RF: Mystery Retina: Interactive Discussion of Challenging Cases, 2008
Mieler WF, Kang Derwent JJ: Advances in Drug Delivery to the Posterior Segment, 2008

American Academy of Ophthalmology

- Ophthalmic Knowledge Assessment Program (OKAP) Written Examination Committee, American Academy of Ophthalmology, 1990-1998
Ophthalmic Knowledge Assessment Program (OKAP)-American Board of Ophthalmology (ABO) Liaison Committee, 1991-1998
Chairman, Ophthalmic Knowledge Assessment Program (OKAP), 1994-1998.
Honor Award, 1992
AAO Council
 ABO representative 1998-99
 Macula Society representative 2000-05
 Chair, Council Credentials Committee 2003
 Subspecialty Section Nominating Committee, 2003
 Pan-American Association Ophthalmology representative 2006-08
 Representative from the Council Section for Subspecialty/Specialized Interest Societies to the AAO Nominating Committee
Member, Task Force on Plaquenil Toxicity, 2000-02.
Member, Complementary Therapy Task Force, 2000-03
Media Spokesperson, 2000-present
Senior Honor Award, 2001
EYENET Editorial Advisory Board, 2003-present
AAO Subspecialty Day Vitreoretinal Program Planning Committee, 2000-03
 Chair, Subspecialty Day Vitreoretinal Program, 2003
Member, Subspecialty Day Advisory Planning Committee, 2004-present
Member, Nominating Committee, 2006-07
Representative to the American College of Surgeons, 2007-present

- Member, National Eye Care Project, 1986-present
National Society to Prevent Blindness - Wisconsin Medical Advisory Committee, 1987-1999
Course Co-Director, The First Midwest Fluorescein Conference, Egg Harbor, WI, August 1989
Course Co-Director, The Second Midwest Fluorescein Conference, Egg Harbor, WI, August 1990
Course Co-Director, Ocular and Orbital Tumors, Milwaukee, WI, December 1990.
Course Co-Director, The Third Midwest Fluorescein Conference, Egg Harbor, WI, August 1991
Course Co-Director, The Fourth Midwest Fluorescein Conference, Egg Harbor, WI, August 1992
Course Co-Director, The Fifth Midwest Fluorescein Conference, Jackson Hole, WY, August, 1993
Course Co-Director, The Sixth Midwest Fluorescein Conference, Traverse City, MI, August 1994

- Course Director, The Seventh Midwest Fluorescein Conference, Lake Geneva, WI, August 1995
- Course Director, The Eighth Midwest Ocular Angiography Conference, Lake Louise, Alberta, Canada, August 1996
- Course Director, The Ninth Midwest Ocular Angiography Conference, Lake Geneva, WI, August 1997.
- Course Director, The Tenth Midwest Ocular Angiography Conference, Sundance, UT, July 1998.
- Course Director, The Eleventh Midwest Ocular Angiography Conference, Whistler, British Columbia, Canada, August 1999.
- Course Director, The Twelfth Midwest Ocular Angiography Conference, Girdwood, AK, June 2000.
- Course Director, New Developments in the Management of Age-Related Macular Degeneration, Baylor College of Medicine, Houston, TX, February 2000
- Course Director, Emerging Treatments for Exudative Age-Related Macular Degeneration, Baylor College of Medicine, Houston, TX, May 2000
- Course Director, Top of the World Comprehensive Ophthalmology Symposium, Girdwood, AK, June 2000
- Course Director, Uveitis Update. Baylor College of Medicine, Houston, TX, November 2000
- Course Co-Director, Southwest Vitreoretinal Symposium, San Antonio, TX, June 2001
- Course Director, The Thirteenth Midwest Ocular Angiography Conference, Lake Louise, Alberta, Canada, August 2001
- Course Director, Pediatric Retina Update, Baylor College of Medicine, Houston, TX, August 2001
- Course Co-Director, The Second Annual Southwest Vitreoretinal Symposium, and Vitreoretinal Fellow's Forum, San Antonio, TX, July 2002
- Course Director, The Fourteenth Midwest Ocular Angiography Conference, Park City, UT, August 2002
- Course Director, The Fifteenth Annual Midwest Ocular Angiography Conference, Jasper, Alberta, Canada, August 2003
- Course Co-Director, The Third Annual Southwest Vitreoretinal Symposium, and Vitreoretinal Fellow's Forum, San Antonio, TX, September 2003
- Course Director, The Sixteenth Annual Midwest Ocular Angiography Conference, Grand Teton National Park, Moran, WY, June 2004
- Course Co-Director, The Fourth Annual Southwest Vitreoretinal Symposium, and Vitreoretinal Fellow's Forum, San Antonio, TX, September 2004
- Course Director, The Seventeenth Annual Midwest Ocular Angiography Conference, Whistler, BC, Canada, August 2005
- Course Director, The Fifth Annual Advanced Vitreoretinal Techniques & Technology (AVTT) symposium and Continuing Program Education (CPE) Vitreoretinal Fellow's Forum, Chicago, August 2005
- Course Director, The Eighteenth Annual Midwest Ocular Angiography Conference, Girdwood, AK, August 2006
- Course Director, The Sixth Annual Advanced Vitreoretial Techniques & Technology (AVTT) symposium and Continuing Professional Education (CPE) Vitreoretinal Fellow's Forum, Chicago, September, 2006
- Course Director, The Nineteenth Annual Midwest Ocular Angiography Conference, St. John's, Newfoundland, Canada, August 2007
- Course Director, The Seventh Annual Advanced Vitreoretial Techniques & Technology (AVTT) symposium and Continuing Professional Education (CPE) Vitreoretinal Fellow's Forum, Chicago, September 2007

Course Director, The Twentieth Annual Midwest Ocular Angiography Conference,
Lake Louise, Alberta, Canada, August 2008
Course Director, The Eighth Annual Advanced Vitreoretial Techniques & Technology
(AVTT) symposium and Continuing Education Program (CPE) Vitreoretinal
Fellow's Forum, Chicago, August 2008

Project ORBIS

Participating surgeon, Kingston, Jamaica, November 1990
Participating surgeon, Port of Spain, Trinidad & Tobago, March 1997
Participating surgeon, Kuala Lumpur, Malaysia, November 2004
Member, Research to Prevent Blindness, 1991-present
Basic Course in Ophthalmology Faculty (Guillermo Pico Santiago), University of
Puerto Rico, San Juan, Puerto Rico, 1991-98
Lancaster Course Faculty, Waterville, ME, 1991-2005
Retina Section, Co-Director 1992-2005
Excellence in Teaching Award 1998
Advanced Medical Retina Symposium Faculty, San Francisco, CA, May 1991
Course Director, Medical College of Wisconsin Advanced Vitreoretinal Surgery
Symposium, Milwaukee, WI, July 1991
United States Eye Injury Registry, Member of Board of Directors,
1991-present
Member, Executive Committee 1994-present
Vice-President, 1994-95
Scientific Director, Wisconsin Eye Injury Registry (WEIR), 1991-99
Association for Research in Vision and Ophthalmology (ARVO)
Retina, Program Planning Committee 1993-95
Retina, Program Planning Committee Co-chairman 1994-95
Long Range Planning Committee, Subcommittee on the ARVO Annual Meeting
1994-95

Scientific Referee

Archives of Ophthalmology, 1987-present
Editorial Board member, 1994-2006
CME Section Editor, 1998-2005
American Journal of Ophthalmology, 1988-present
RETINA, 1988-present
Editorial Board member, 1995-2004
Editor, Photo Essay section, 2000-02
Ophthalmology, 1989-present
Diabetes, 1991-present
Investigative Ophthalmology and Visual Science, 1992-present
New England Journal of Medicine, 1994-present
Journal of Pediatric Ophthalmology & Strabismus, 1995-present
Survey of Ophthalmology, 1996-present
Ophthalmic Surgery and Lasers, 1997-present
Ophthalmic Epidemiology, 1998-present
Journal of the American Medical Association (JAMA), 1999-present
Cornea, 2000-present
British Journal of Ophthalmology, 2001-present
Ophthalmic Plastic and Reconstructive Surgery, 2002-present
Journal of Cataract & Refractive Surgery, 2002-present
Expert Opinion on Drug Safety, 2002-present

Cornea, 2004-present
Eye, 2007-present
von Graefes Clinical and Experimental Ophthalmology, 2007-present

Textbook Editing

Section Editor, Retinal Surgery, in Albert DM, ed., *Ophthalmic Surgery: Principles and Practice*. Blackwell Science, Cambridge, MA
Section Editor, Ocular Trauma, in Albert DM and Jakobiec FA, eds., *Albert and Jakobiec's Principles and Practice of Ophthalmology, 2nd edition*, W.B.Saunders Company, Philadelphia, PA
Section Editor, Ocular Trauma, in Albert DM, Miller JW, eds., *Albert and Jakobiec's Principles and Practice of Ophthalmology, 3rd Edition*, W.B. Saunders Company, Philadelphia, PA, 2008
Section Editor, Vitreous, in Gold DH, Lewis RA, eds., *The Clinical Atlas*. American Medical Association, Chicago, IL, 2002.
Editor, *Ocular Trauma and Emergencies: Medical and Surgical Management* American Academy of Ophthalmology, 2004-in preparation
Editor, *Age-Related Macular Degeneration: A Comprehensive Textbook*. Eds., Alfaro DV III, Liggett PE, Mieler WF, Quiroz-Mercado H, Jager RD, Tano Y. Lippincott Williams Wilkins, 2006
Editor, *Macular Surgery, 2nd Edition*, Lippincott, 2008-in preparation
Editor, *Retinal Diseases: Drug Mechanisms and Pharmacotherapy*, Elsevier Publications, 2008-in preparation

American Board of Ophthalmology (ABO)

Associate Examiner, 1988-97

Prop Revision Committee, oral boards, posterior segment, 1990-97

American Board of Ophthalmology (ABO), Board of Directors, 1998-2005

Associate Examiners Committee, 1998-2005

Fellowship Accreditation Committee, 1998-2004

Written Qualifying Examination Committee, 1998-2005

Publications Committee, 1999-2005

American Academy of Ophthalmology Council (alternate), 1998

American Academy of Ophthalmology Council, 1999

Item Review Liaison Committee (WQE & OKAP), 1999-2005

Chairman, Written Exams Committee, 2000-04

Chairman, Item Review Committee, 2000-04

Member, Executive Committee, 2000-05

Member, Nominating Committee, 2002-05

Chairman, Nominating Committee, 2004

Ad hoc, Knowledge Base committee, 2003-05

Chair, Ad hoc, Knowledge Base committee, 2004-05

Vice-Chairman of the ABO 2004

Maintenance of Certification (MOC) Liaison committee with AAO, 2004-present

Chairman of the ABO, 2005

Associate Executive Director, 2006

Emeritus Director, 2006-present

Member, American Board of Medical Specialists (ABMS), 2004-present

Member, Committee of Board Representatives and Executives (COBRE), 2004-05

Member, Committee on Certification, Subcertification, Recertification,
and Maintenance of Certification (COCERT), 2004-present
Member, Board of Directors, 2005-06

Best Doctors in America, Woodward/White, Inc., 1995-96, 1997-98, 1999-2000, 2001-
02, 2003-04, 2005-06, 2007-08
Selected to "America's Top Ophthalmologists", by Consumers' Research Council of
America, 2002-03
Selected America's Top Doctors, Castle Connolly Medical Ltd, 2003-07
Selected Top Doctors in Chicago, 2006-08

Member, Scientific Advisory Board, The Macula Foundation, Inc., New York NY, 1998-
present
Member, Alcon Surgical, Inc., Retina Advisory Council (RAC), 2000-present
Member, Alcon Pharmaceutical Global Advisory Panel, 2004-present
Member, Scientific Board, The Eye Care Foundation, 2001-present
Member, Safety Committee, Anecortave Acetate Clinical Trials, Alcon Surgical, Inc,
2002-08
National Eye Institute (NEI), Special Emphasis Panel grant review, 2002-present
AMD Initiative Steering Committee, 2004-present
The Eyecare Foundation, Scientific Advisory Board member, 2002-present
Editorial Board, Retinal Physician, 2004-present
Advisory Board member, Eyetech Pharmaceuticals, Novartis Pharmaceuticals, Inc.,
and Genentech

PUBLICATIONS

See Addendum #1

**PUBLISHED ABSTRACTS, PRESENTATIONS,
POSTERS AND BOOK REVIEWS**

See Addendum #2

**Addendum #1
PUBLICATIONS**

1. Miller SA, Mieler WF: Systemic reaction to subconjunctival phenylephrine. *Can J Ophthalmol* 13:291-293, 1978.
2. Mieler WF: Diabetes mellitus and the eye. *Diabetes Today* 2:2, 1986.
3. Han DP, Lewis H, Williams GA, Mieler WF, Abrams GW, Aaberg TM: Laser photocoagulation in the acute retinal necrosis syndrome. *Arch Ophthalmol* 105:1051-1054, 1987.
4. Lambrou FH, Chilbert M, Mieler WF, Williams GA, Olsen K: A new technique for subchoroidal implantation of experimental malignant melanoma. *Invest Ophthalmol Vis Sci* 29:995-998, 1988.
5. Glaser BM and Silicone Oil Study Group (Mieler WF): Silicone oil for proliferative vitreoretinopathy. *Arch Ophthalmol* 106:323-324, 1988.
6. Han DP, Mieler WF, Abrams GW, Williams GA: Management of traumatic retinal incarceration with vitrectomy. *Arch Ophthalmol* 106:640-645, 1988.
7. Kronish JW, Mieler WF, Dortzbach RK: Eyelid phimosis and chronic radiation dermatitis following Iridium brachytherapy. *Am J Ophthalmol* 105:431-432, 1988.
8. Mieler WF, Williams DF, Levin M: Vitreous amyloidosis. *Arch Ophthalmol* 106:781-783, 1988.
9. Williams DF, Mieler WF, Abrams GW, Lewis H: Results and prognostic factors in penetrating ocular injuries with retained intraocular foreign bodies. *Ophthalmol* 95:911-916, 1988.
10. Straatsma BR, COMS Study Group (Mieler WF): Enucleation versus plaque irradiation for choroidal melanoma. *Ophthalmol* 95:1000-1004, 1988.
11. Mieler WF, Will BR, Lewis H, Aaberg TM: Vitrectomy in the management of peripheral uveitis. *Ophthalmol* 95:859-864, 1988.
12. Scallon LJ, Burke JM, Mieler WF, Aaberg TM, Kies JC: Canthaxanthine-induced retinal pigment epithelial changes in the cat. *Curr Eye Res* 7:687-693, 1988.
13. Devenyi RG, Mieler WF, Lambrou FH, Will BR, Aaberg TM: Cryopexy of the vitreous base in the management of peripheral uveitis. *Am J Ophthalmol* 105:136-138, 1988.
14. Sternberg P, Han DP, Yeo JH, Barr CC, Lewis H, Williams GA, Mieler WF: Photocoagulation to prevent retinal detachment in acute retinal necrosis (ARN). *Ophthalmol* 95:1389-1393, 1988.

15. Jaffe GJ, Williams GA, Mieler WF, Radius RL: Ab interno sclerostomy with a high powered endolaser. *Am J Ophthalmol* 106:391-396, 1988.
16. Williams DF, Mieler WF, Lewandowski M, Greenberg M: Echographic verification of radioactive plaque position in the treatment of melanoma. *Arch Ophthalmol* 106:1623-1624, 1988.
17. Boone DC, Azen SP, Irvine A, and The Silicone Study Group: The validity and reliability of photographic documentation of proliferative vitreoretinopathy (PVR). *Controlled Clinical Trials* 9:275, 1988.
18. Jaffe GJ, Mieler WF, Williams GA: Photoablation of ocular melanoma with a high-powered argon endolaser. *Arch Ophthalmol* 107:113-118, 1989.
19. Azen SP, Irvine AR, Davis MD, Stern W, Lonn L, Hilton G, Schwartz A, Boone D, Qullen-Thomas B, Lyons M, Lean JS, and the Silicone Study Group (Mieler WF): The validity and reliability of photographic documentation of proliferative vitreoretinopathy. *Ophthalmol* 96:352-357, 1989.
20. Mieler WF: Closed vitrectomy and chronic uveitis. *Seminars in Ophthalmology* 4:1-8, 1989.
21. Williams DF, Williams GA, Hartz A, Mieler WF, Abrams GW, Aaberg TM: Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique. *Ophthalmol* 96:752-758, 1989.
22. Lean JS, Stern WH, Irvine AR, Azen SP, and the Silicone Study Group (Mieler WF): Classification of proliferative vitreoretinopathy used in the silicone study. *Ophthalmol* 96:765-771, 1989.
23. Williams DF, Mieler WF, Lewandowski M: Resolution of an apparent choroidal melanoma. *Retina* 9:131-135, 1989.
24. Williams GA, Abrams GW, Mieler WF: Illuminated retinal picks for vitreous surgery. *Arch Ophthalmol* 107:1016, 1989.
25. Jaffe GJ, Mieler WF, Radius RL, Kincaid MC, Massaro BM, Abrams GW: Ab interno sclerostomy with a high-powered argon endolaser - clinicopathologic correlation. *Arch Ophthalmol* 107:1183-1185, 1989.
26. Mieler WF, Jaffe GJ, Steeves R: Ferromagnetic hyperthermia and Iodine-125 brachytherapy in the treatment of choroidal melanoma in a rabbit model. *Arch Ophthalmol* 107:1524-1528, 1989.
27. Han DP, Lewis H, Lambrou FH, Mieler WF, Hartz A.: Mechanisms of intraocular pressure elevation after pars plana vitrectomy. *Ophthalmol* 96:1357-1362, 1989.

28. Lewis H, Aaberg TM, Abrams GW, McDonald HR, Williams GA, Mieler WF: Subretinal membranes in proliferative vitreoretinopathy. *Ophthalmol* 96:1403-1415, 1989.
29. Chamberlain JA, Bressler NM, Bressler SB, Elman MJ, Murphy RP, Flood TP, Hawkins BS, Maguire MG, Fine SL, The Macular Photocoagulation Study Group (Mieler WF): The use of photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in the Macular Photocoagulation Study. *Ophthalmol* 96:1526-1534, 1989.
30. Nichols CJ, Mieler WF: Severe retinal vaso-occlusive disease secondary to procainamide-induced lupus. *Ophthalmol* 96:1535-1540, 1989.
31. Williams DF, Mieler WF: Long-term follow-up of acute multifocal posterior placoid pigment epitheliopathy. *Br J Ophthalmol* 73:985-990, 1989.
32. Williams DF, Mieler WF, Lewandowski M: Resolution of an apparent melanoma. (Response to Letter to Editor) *Retina* 9:337, 1989.
33. Boone DC, Lai M, Azen S, and The Silicone Study Group (Mieler WF): Clinical judgment and centralized data management. *Controlled Clinical Trials* 10:339, 1989.
34. Boone DC and The Silicone Study Group (Mieler WF): Testing protocol knowledge of clinic coordinators. *Controlled Clinical Trials* 11:305, 1990.
35. Williams DF, Mieler WF, Jaffe GJ, Robertson DM, Hendrix L: Magnetic resonance imaging of juxtapapillary radioactive plaques in cadaver eyes. *Br J Ophthalmol* 74:43-46, 1990.
36. Sneed SR, Pulido JS, Blodi CF, Clarkson JG, Flynn HW, Mieler WF: Surgical management of late-onset retinal detachments associated with regressed retinopathy of prematurity. *Ophthalmol* 97:179-183, 1990.
37. Koenig SB, Han DP, Mieler WF, Abrams GW: Combined phacoemulsification and pars plana vitrectomy. *Arch Ophthalmol* 108:362-364, 1990.
38. Erie JC, Robertson DM, Mieler WF: Presumed small choroidal melanomas with serous macular detachments: follow-up observations with and without surface photocoagulation treatment. *Am J Ophthalmol* 109:259-264, 1990.
39. Williams DF, Mieler WF, Abrams GW: Intraocular foreign bodies in young people. *Retina* 10(Suppl):45-49, 1990.
40. Williams DF, Mieler WF, Williams GA: Posterior segment manifestations of ocular trauma. *Retina* 10(Suppl):35-44, 1990.
41. Mieler WF: The Third National Eye Trauma Symposium (Editorial). *Retina* 10(Suppl):5A-6A, 1990.

42. Williams DF, Bennett SR, Abrams GW, Han DP, Mieler WF, Jaffe GJ, Williams GA: Low dose intraocular tissue plasminogen activator for treatment of postvitrectomy fibrin formation [Letter to the Editor]. *Am J Ophthalmol* 109:606-607, 1990.
43. Han DP, Lewis MT, Kuhn EM, Abrams GW, Mieler WF, Williams GA, Aaberg TM: Relaxing retinotomies: surgical results and risk factors for failure. *Arch Ophthalmol* 108:694-697, 1990.
44. Shields JA, Glazer LC, Mieler WF, Shields CL, Gottlieb MS: Comparison of xenon arc and argon laser photocoagulation in the treatment of small choroidal melanomas. *Am J Ophthalmol* 109:647-655, 1990.
45. Jaffe GJ, Schwartz D, Han DP, Gottlieb M, Hartz A, McCarty D, Mieler WF, Abrams GW: Risk factors for postvitrectomy fibrin formation. *Am J Ophthalmol* 109:661-667, 1990.
46. Macular Photocoagulation Study Group (Mieler WF): Krypton Laser photocoagulation for neovascular lesions of age-related macular degeneration. *Arch Ophthalmol* 108:816-824, 1990.
47. Macular Photocoagulation Study Group (Mieler WF): Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. *Arch Ophthalmol* 108:825-831, 1990.
48. Macular Photocoagulation Study Group (Mieler WF): Krypton laser photocoagulation for idiopathic neovascular lesions. *Arch Ophthalmol* 108:832-837, 1990.
49. Schachat AP, Markowitz JA, Hawkins BS, Fine SL, The COMS Study Group (Mieler WF): Non-ocular cancers in patients with choroidal melanoma [Letter to the Editor]. *Ophthalmology* 97:837-838, 1990.
50. The Collaborative Ocular Melanoma Study Group (Mieler WF): Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS Report No. 1. *Arch Ophthalmol* 108:1268-1273, 1990.
51. Williams DF, Peters MA, Abrams GW, Han DP, Mieler WF: A two-stage technique for intraoperative fluid-gas exchange following pars plana vitrectomy. *Arch Ophthalmol* 108:1484-1486, 1990.
52. Bressler SB, Maguire MG, Bressler NM, Fine SL, the Macular Photocoagulation Study Group (Mieler WF): Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. *Arch Ophthalmol* 108:1442-1447, 1990.
53. Han DP, Mieler WF, Schwartz DM, Abrams GW: Management of traumatic hemorrhagic retinal detachment during pars plana vitrectomy. *Arch Ophthalmol* 108:1281-1286, 1990.

54. Glazer LC, Mieler WF, Devenyi RG, Burton TC: Complications of primary scleral buckling procedures in high myopia. *Retina* 10:170-172, 1990.
55. Mieler WF, Ellis MK, Williams DF, Han DP: Retained intraocular foreign bodies and endophthalmitis. *Ophthalmology* 97:1532-1538, 1990.
56. Mieler WF, Platt LW, Bennett SR, Koenig SB: Localized retinal detachment and combined central retinal artery and vein occlusion after retrobulbar anesthesia. *Retina* 10:278-283, 1990.
57. Barlow W, Azen S, and The Silicone Oil Study Group (Mieler WF): The effect of therapeutic treatment crossovers on the power of clinical trials. *Controlled Clinical Trials* 11:314-326, 1990.
58. Feist RM, Lim JI, Joondeph BC, Pflugfelder SC, Mieler WF, Ticho BH, Resnick K: Penetrating ocular injury from contaminated eating utensils. *Arch Ophthalmol* 109:63-66, 1991.
59. Mieler WF, Williams DF, Sneed SR, Williams GA: Systemic therapeutic agents and retinal toxicity. *Seminars in Ophthalmology* 6:45-64, 1991.
60. Sneed S, Frazier-Byrne S, Mieler WF, Nicholson DH, Olsen KR, Hughes R: Choroidal detachment associated with metastatic choroidal tumors. *Ophthalmology* 98:963-970, 1991.
61. Nichols CJ, Boldt HC, Mieler WF, Han DP, Olsen K: Ocular injuries caused by elastic cords. *Arch Ophthalmol* 109:371-372, 1991.
62. Azen SP, Boone DC, Barlow W, McCuen BW, Walonker F, Anderson MM, Lean JS, Mowery RL, Ryan SJ, Stern W, and The Silicone Study Group (Mieler WF): Methods, statistical features and baseline results of a standardized, multicentered ophthalmologic surgical trial: The Silicone Study. *Controlled Clinical Trials* 12:438-455, 1991.
63. Han DP, Lewandowski M, Mieler WF: Echographic diagnosis of anterior hyaloidal fibrovascular proliferation. *Arch Ophthalmol* 109:842-846, 1991.
64. Murray TG, Boldt HC, Lewis H, Abrams GW, Mieler WF, Han DP: A technique for facilitated dissection and visualization of the vitreous base, pars plana and pars plicata. *Arch Ophthalmol* 109:1458-1459, 1991.
65. Han DP, Murphy ML, Mieler, WF, Abrams GW: Outpatient fluid-air exchange for severe postvitrectomy diabetic vitreous hemorrhage: long-term results and complications. *Retina* 11:309-314, 1991.
66. Palay DA, Sternberg P, Davis J, Lewis H, Holland GN, Mieler WF, Jabs DA, Drews C: Decrease in the risk of bilateral involvement in acute retinal necrosis by acyclovir therapy. *Am J Ophthalmol* 112:250-255, 1991.

67. Folk JC, Blackhurst DW, Alexander J, Elman MJ, Phillips DA, Macular Photocoagulation Study Group (Mieler WF): Pretreatment fundus characteristics as predictors of recurrent choroidal neovascularization (letter to the editor). *Arch Ophthalmol* 109:1193-1194, 1991.
68. Macular Photocoagulation Study Group (Mieler WF): Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. *Arch Ophthalmol* 109:1109-1114, 1991.
69. Macular Photocoagulation Study Group (Mieler WF): Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. *Arch Ophthalmol* 109:1220-1231, 1991.
70. Macular Photocoagulation Study Group (Mieler WF): Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. *Arch Ophthalmol* 109:1232-1241, 1991.
71. Macular Photocoagulation Study Group (Mieler WF): Subfoveal neovascular lesions in age-related macular degeneration: Guidelines for evaluation and treatment in the Macular Photocoagulation Study. *Arch Ophthalmol* 109:1242-1257, 1991.
72. Schachat AP, Robertson DM, Mieler WF, Schwartz D, Augsburger JJ, Schatz H, Gass JDM: Sclerochoroidal calcification. *Arch Ophthalmol* 110:196-199, 1992.
73. Han DP, Mieler WF, Burton TC, Brower MF: Submacular fibrosis after photocoagulation for diabetic macular edema. *Am J Ophthalmol* 113:513-521, 1992.
74. Orr PR, Blackhurst DW, Hawkins BS, Macular Photocoagulation Study Group (Mieler WF): Patient and clinic factors predictive of missed visits and inactive status in a multicenter clinical trial. *Controlled Clinical Trials* 13:40-49, 1992.
75. The Silicone Study Group (Mieler WF): Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Oil Study Report 1. *Arch Ophthalmol* 110:770-779, 1992.
76. The Silicone Study Group (Mieler WF): Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Oil Study Report 2. *Arch Ophthalmol* 110:780-792, 1992.
77. Dannenberg AL, Parver LM, Brechner RJ, Khoo L, and the National Eye Trauma System Investigators (Mieler WF): Penetrating eye injuries in the workplace. The National Eye Trauma System Registry. *Arch Ophthalmol* 110:843-848, 1992.
78. Dannenberg AL, Parver LM, Fowler CJ, and the National Eye Trauma System Investigators (Mieler WF): Penetrating eye injuries related to assault. The National Eye Trauma System Registry. *Arch Ophthalmol* 110:849-852, 1992.

79. Glazer LC, Mieler WF, Bennett SR: Hemorrhage associated with localization of melanoma margins during radioactive plaque placement. *Can J Ophthalmol* 27:177-180, 1992.
80. Koenig SB, Mieler WF, Han DP, Abrams GW: Combined phacoemulsification, pars plana vitrectomy and posterior chamber intraocular lens insertion. *Arch Ophthalmol* 110:1101-1104, 1992.
81. Steeves RA, Murray TG, Moros EG, Boldt HC, Mieler WF, Paliwal BR: Concurrent ferromagnetic hyperthermia and Iodine-125 brachytherapy in a rabbit choroidal melanoma model. *International J Hyperthermia* 8:443-449, 1992.
82. Michels M, Lewis H, Abrams GW, Han DP, Mieler WF, Neitz J: Macular phototoxicity caused by fiberoptic endoillumination during pars plana vitrectomy. *Am J Ophthalmol* 114:287-296, 1992.
83. Blumenkranz MS, Ward T, Murphy S, Mieler W, Williams GA, Long J: Applications and limitations of vitreoretinal biopsy techniques in intraocular large cell lymphoma. *Retina* 12:S64-S70, 1992.
84. Boldt HC, Abrams GW, Murray TG, Han DP, Mieler WF: The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin. *Retina* 12:S75-S79, 1992.
85. Kim DD, Mieler WF, Wolf MD: Fundus changes in membranoproliferative glomerulonephritis. *Am J Ophthalmol* 114:593-599, 1992.
86. Mieler WF, Glazer LC, Bennett SR, Han DP: Favorable outcome of traumatic endophthalmitis with associated retinal breaks or detachment. *Can J Ophthalmol* 27:348-352, 1992.
87. Eye Disease Case-Control Study Group (Mieler WF): Risk factors for neovascular age-related macular degeneration. *Arch Ophthalmol* 110:1701-1708, 1992.
88. Eye Disease Case-Control Study Group (Mieler WF): Antioxidant status and neovascular age-related macular degeneration. *Arch Ophthalmol* 111:104-109, 1993.
89. Groessl S, Nanda SK, Mieler WF: Penetrating ocular trauma secondary to assaultive trauma. *Am J Ophthalmol* 116:26-33, 1993.
90. Piper JG, Han DP, Abrams GW, Mieler WF: Perioperative choroidal hemorrhage at pars plana vitrectomy: a case control study. *Ophthalmology* 100:699-704, 1993.
91. Keithahn MAZ, Bennett SR, Cameron D, Mieler WF: Retinal folds in Terson's syndrome. *Ophthalmology* 100:1187-1190, 1993.

92. Thompson JT, Parver LM, Enger CL, Mieler WF, Liggett PE, for the National Eye Trauma System: Infectious endophthalmitis after penetrating injuries with retained intraocular foreign bodies. *Ophthalmology* 100:1468-1474, 1993.
93. Macular Photocoagulation Study Group (Mieler WF): Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal neovascular membranes. *Arch Ophthalmol* 111:1189-1199, 1993.
94. Macular Photocoagulation Study Group (Mieler WF): Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. *Arch Ophthalmol* 111:1200-1209, 1993.
95. McCuen BW II, Azen SP, Stern W, Lai MY, Lean JS, Linton KLP, Ryan SJ, and the Silicone Study Group (Mieler WF): Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy. Results in Group 1 versus Group 2 (Silicone Study Report #3). *Retina* 13:279-284, 1993.
96. Collaborative Ocular Melanoma Study Group (Mieler WF): Design and methods of a clinical trial for a rare condition: The Collaborative Ocular Melanoma Study: Report No. 3. *Controlled Clinical Trials* 14:362-391, 1993.
97. Blumenkranz MS, Azen SP, Aaberg TM, Boone DC, Lewis H, Radtke N, Ryan SJ, and the Silicone Oil Study Group (Mieler WF): Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy. *Silicone Study Report 5. Am J Ophthalmol* 116:557-564, 1993.
98. Nanda SK, Mieler WF, Murphy ML: Penetrating ocular injuries secondary to motor vehicle accidents. *Ophthalmol* 100:201-207, 1993.
99. Mieler WF: Pars Planitis. Consultant, Focal Points, Clinical Modules for Ophthalmologists. *American Academy of Ophthalmology* 11:8-11, 1993.
100. Barr CC, Linton KLP, Abrams G, Trese M, Lai MY, Azen SP, Ryan SJ, and The Silicone Oil Study Group (Mieler WF): Intraocular pressure abnormalities in the Silicone Study (Silicone Study Report #4). *Ophthalmology* 100:1629-1635, 1993.
101. Ryan SJ, Azen SP: Response to Letter to the Editor. *Arch Ophthalmol* 111:428-429, 1993.
102. Han DP, Piper JG, Abrams GW, Mieler WF: Choroidal hemorrhage at vitrectomy [response to Letter to the Editor]. *Ophthalmology* 101:215, 1994.
103. Connor TB, Wolf MD, Arrindell EL, Mieler WF: Surgical removal of an extrafoveal disciform scar with foveal serous detachment in age-related macular degeneration. *Retina* 14:125-129, 1994.

104. Han DP, Rychwalski PJ, Mieler WF, Abrams GW: Management of complex retinal detachment with combined relaxing retinotomy and intravitreal perfluoro-n-octane injection. *Am J Ophthalmol* 118:24-32, 1994.
105. Han DP, Murphy ML, Mieler WF: A modified en bloc excision technique during vitrectomy for diabetic traction retinal detachment: results and complications. *Ophthalmology* 101:803-808, 1994.
106. Han DP, Wang Q, Hartz A, Jaffe GJ, Murray TG, Boldt HC, Arrindell EL, Coe E, Abrams GW, Mieler WF: Postoperative fibrin formation and visual outcome after pars plana vitrectomy. *Retina* 14:225-230, 1994.
107. Mieler WF, Malinowski SM: Current evaluation and therapy of pars planitis. *Vitreoretinal Surgery and Technology* 6:3-4, 1994.
108. Pulido JS, Beecher D, Mieler WF: The effect of toxins in endophthalmitis. *Vitreoretinal Surgery and Technology* 6:6-8, 1994.
109. Hutton WL, Azen SP, Blumenkranz MS, Lai MY, McCuen BW, Han D, Flynn HW, Ramsey RC, Ryan SJ, for the Silicone Oil Study Group: The effects of silicone oil removal in the Silicone Oil Study (Silicone Study Report #6). *Arch Ophthalmol* 112:778-785, 1994.
110. Schachat AP: Management of uveal melanoma: a continuing dilemma. The Collaborative Ocular Melanoma Study Group. *Cancer* 74:3073-3075, 1994.
111. Macular Photocoagulation Study Group: Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. *Arch Ophthalmol* 112:500-509, 1994.
112. Macular Photocoagulation Study Group: Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. *Arch Ophthalmol* 112:480-488, 1994.
113. Hutton WL, Azen SP, Lee MBF, Blumenkranz MS, Lai MY, McCuen BW, Han DP, Flynn HW Jr, Ramsey RC, Ryan SJ, the Silicone Study Group: The effects of silicone oil removal. Silicone Study report 6. *Arch Ophthalmol* 112:778-785, 1994.
114. Arrindell EL, Wu JC, Wolf MD, Nanda S, Han DP, Wong EC, Abrams GW, Mieler WF, Hyde JS: High resolution magnetic resonance imaging evaluation of blood-retinal barrier integrity following transscleral diode laser treatment. *Arch Ophthalmol* 113:96-102, 1995.
115. Macular Photocoagulation Study Group: Laser photocoagulation for neovascular lesions nasal to the fovea. Results from clinical trials for lesions secondary to ocular histoplasmosis or idiopathic causes. *Arch Ophthalmol* 113:56-61, 1995.

116. Malinowski SM, Mieler WF, Koenig SB, Han DP, Pulido JS: Combined pars plana vitrectomy/lensectomy and open loop anterior chamber lens implantation. *Ophthalmology* 102:211-216, 1995.
117. Murphy ML, Mieler WF, Williams DR, Lewandowski M: Extrac scleral pseudoextension of uveal melanomas. *von Graefe's Clin Exp Arch Ophthalmol* 233:399-406, 1995.
118. Liggett PE, Skolik SA, Horio B, Saito Y, Alfaro DV, Mieler WF: Human autologous serum for the treatment of full-thickness macular holes. A preliminary study. *Ophthalmology* 102:1071-1076, 1995.
119. Han DP, Pulido JS, Mieler WF, Johnson MW: Vitrectomy for proliferative diabetic retinopathy with severe equatorial fibrovascular proliferation. *Am J Ophthalmol* 119:563-570, 1995.
120. Abrams GW, Azen SP, Barr CC, Lai MY, Hutton WL, Trese MT, Irvine A, Ryan SJ, and the Silicone Study Group: The incidence of corneal abnormalities in the Silicone Study (Silicone Study Report #7). *Arch Ophthalmol* 113:764-769, 1995.
121. Chaudhry NA, Lim ES, Saito Y, Mieler WF, Liggett PE: Early vitrectomy and endolaser photocoagulation in patients with Type I diabetes with severe vitreous hemorrhage. *Ophthalmol* 102:1164-1169, 1995.
122. Cohen SM, Flynn HW, Murray TG, Smiddy WE, and the Endophthalmitis after Vitrectomy Study Group: Endophthalmitis after pars plana vitrectomy. *Ophthalmology* 102:705-712, 1995.
123. Macular Photocoagulation Study Group: The influence of treatment extent on the visual acuity of eyes treated with krypton laser for juxtafoveal choroidal neovascularization. *Arch Ophthalmol* 113:190-194, 1995.
124. Chang TS, Aylward GW, Davis JL, Mieler WF, Oliver G, Maberly A, Gass JDM, The Retinal Vasculitis Study Group: Idiopathic retinal vasculitis, aneurysms, and neuroretinitis. *Ophthalmology* 102:1089-1097, 1995.
125. Mieler WF, Nanda SK, Wolf MD, Harman J: Golf-related ocular injuries. *Arch Ophthalmol* 113:1410-1413, 1995.
126. Kangas TA, Bennett SR, Flynn HW Jr, Murray TG, Rubsamen PE, Han DP, Mieler WF, Williams DF, Abrams GW: Reversible loss of light perception after vitreoretinal surgery. *Am J Ophthalmol* 120:751-756, 1995.
127. Cox MS, Azen SP, Barr CC, Linton KLP, Diddie DR, Lai MY, Freeman HM, Irvine A, and the Silicone Study Group: Macular pucker after successful surgery for proliferative vitreoretinopathy (Silicone Study Report #8). *Ophthalmology* 102:1884-1891, 1995.

128. Park SE, Mieler WF, Pulido JS: Peripheral scatter photocoagulation for neovascularization associated with pars planitis. *Arch Ophthalmol* 113:1277-1280, 1995.
129. Endophthalmitis Vitrectomy Study Group: Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of post-operative bacterial endophthalmitis. *Arch Ophthalmol* 113:1479-1496, 1995.
130. Kim JW, Freeman WR, El-Haig W, Maguire AM, Arevalo JF, Azen SP, the Vitrectomy for Macular Hole Study Group: Baseline characteristics, natural history and risk factors to progression in eyes with Stage 2 macular holes: results from a prospective randomized clinical trial. *Ophthalmology* 102:1818-1828, 1995.
131. Steeves RA, Tompkins DT, Nash RN, Blair JR, Gentry LL, Paliwal BR, Murray TG, Mieler WF: Thermoradiotherapy of intraocular tumors in an animal model: concurrent versus sequential brachytherapy and ferromagnetic hyperthermia. *Int J Rad Oncol Biol Phys* 33:659-662, 1995.
132. Vinger PF, Mieler WF, Ostreicher JH, Easterbrook M: Ruptured globes following radial keratotomy (RK) and hexagonal (HK) keratotomy surgery. *Arch Ophthalmol* 114:129-134, 1996.
133. McDonald HR, Schatz H, Johnson RN, Abrams GW, Brown GC, Brucker AT, Han DP, Lewis H, Mieler WF, Meyers S: Vitrectomy in eyes with peripheral retinal angioma associated with traction macular detachment. *Ophthalmology* 103:329-334, 1996.
134. Lean J, Azen SP, Lopez P, Qian D, Lai MY, McCuen B, for the Silicone Study Group: The prognostic utility of the Silicone Study Classification System (Silicone Study Report #9). *Arch Ophthalmol* 114:286-292, 1996.
135. McCabe CM, Mieler WF: Six-year follow-up of idiopathic vasoproliferative tumor. *Arch Ophthalmol* 114:617, 1996.
136. Macular Photocoagulation Study (MPS) Group: Occult choroidal neovascularization: Influence on visual outcome in patients with age-related macular degeneration. *Arch Ophthalmol* 114:400-412, 1996.
137. Koenig SB, Mieler WF: The management of ectopia lentis in a family with Marfan's syndrome. *Arch Ophthalmol* 114:1058-1061, 1996.
138. The Macular Photocoagulation Study Group: Five-year follow-up of eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. *Arch Ophthalmol* 114:677-688, 1996.
139. Diddie KR, Azen SP, Freeman HM, Boone DS, Aaberg TM, Lewis H, Radtke NA, Ryan SJ, for the Silicone Study Group: Anterior proliferative vitreoretinopathy in the Silicone Study (Silicone Study Report #10). *Ophthalmology* 103:1092-1099, 1996.

140. Kim JW, Freeman WF, Azen SP, El-Haig W, Klein DJ, Bailey IL, and the Vitrectomy for Macular Hole Study Group: Prospective randomized trial of vitrectomy or observation for stage 2 macular holes. *Am J Ophthalmol* 121:605-614, 1996.
141. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, Kelsey SF, and the Endophthalmitis Vitrectomy Study Group: Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. *Am J Ophthalmol* 122:1-17, 1996.
142. Wells CG, Bradford RH, Fish GE, Hawkins BS, for the COMS Group: Choroidal melanomas in American Indians. *Arch Ophthalmol* 114:1017-1018, 1996.
143. Law SK, Kalenak JW, Connor TB, Pulido JS, Dan DP, Mieler WF: Retinal complications after aqueous shunt surgical procedures for glaucoma. *Arch Ophthalmol* 114:1473-1480, 1996.
144. Endophthalmitis Vitrectomy Study Group: Microbiologic factors and visual outcome in the Endophthalmitis Vitrectomy Study. *Am J Ophthalmol* 122:880-846, 1996.
145. The Eye Disease Case-Control Study: Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group. *Arch Ophthalmol* 114:545-554, 1996.
146. Mitra RA, Pollack JS, Mieler WF: The development of bull's eye maculopathy in a patient with arcuate pigment epithelial dystrophy. *Retina* 17:551-553, 1997.
147. Freeman WR, Kim JW, Azen SP, Kim JW, El-Haig W, Mishell DR III, Bailey I, for the Vitrectomy for Macular Hole Study Group: Vitrectomy for the treatment of full-thickness Stage 3 or 4 macular holes: results of a multicentered randomized clinical trial. *Arch Ophthalmol* 115:11-21, 1997.
148. Haimovici R, Gragoudas ES, Gregor Z, Pesavento RD, Mieler WF, Duker JS: Choroidal metastases from renal cell carcinoma. *Ophthalmol* 104:1152-1158, 1997.
149. Collaborative Ocular Melanoma Study Group: Mortality in patients with small choroidal melanomas. *Arch Ophthalmol* 113:886-893, 1997.
150. Pieramici DJ, Sternberg P Jr, Aaberg TM Sr, Bridges WZ Jr, Capone A, Cardillo JA, deJuan E, Kuhn F, Meredith TA, Mieler WF, Olsen TW, Rubsamen P, Stout T (The Ocular Trauma Classification Group): A system for classifying mechanical injuries of the eye (globe). *Am J Ophthalmol* 123:820-831, 1997.
151. Abrams GW, Azen SP, McCuen BW, Flynn HW Jr, Lai MY, Ryan SJ, for the Silicone Study Group: Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: Results of additional and long-term follow-up (Silicone Study Report #11). *Arch Ophthalmol* 115:335-344, 1997.
152. Tang W, Pulido JS, Mieler WF: HLA-DR15+ Intermediate Uveitis as a Distinct Entity and its Clinical Features. *Am J Ophthalmol* 123:70-75, 1997.

153. McCabe CM, Mieler WF, Postel EA: Idiopathic sclerochoroidal calcification in a 41 year old female. *Arch Ophthalmol* 115:1082-1083, 1997.
154. Johnson MW, Doft BH, Kelsey SF, Barza M, Wilson LA, Barr CC, Wisniewski SR, and the Endophthalmitis Vitrectomy Study Group: The Endophthalmitis Vitrectomy Study: Relationship between clinical presentation and microbiologic spectrum. *Ophthalmol* 104:261-273, 1997.
155. Bannerman TL, Rhoden DL, McAllister SK, Miller JM, Wilson LA, for the EVS Study Group: The source of coagulase negative staphylococci in the Endophthalmitis Vitrectomy Study. *Arch Ophthalmol* 115:357-364, 1997.
156. Wisniewski SR, Hammer ME, Grizzard WS, Kelsey SF, Everett D, Packo KH, Yarian DL, Doft BH, for the EVS Study Group: The investigation of hospital charges related to the treatment of endophthalmitis in the Endophthalmitis Vitrectomy Study. *Arch Ophthalmol* 104:739-745, 1997.
157. Pharmacological Therapy for Macular Degeneration Study Group: Interferon Alfa-2a is Ineffective for Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Results of a Prospective Randomized Placebo-Controlled Clinical Trial. *Arch Ophthalmol* 115:865-872, 1997.
158. Aaberg TM Jr, Rubsamen PE, Flynn HW Jr, Chang S, Mieler WF, Smiddy WE: Dropped nuclei and giant retinal tears as a complication of cataract surgery. *Am J Ophthalmol* 124:222-226, 1997.
159. Murray TG, Steeves RA, Gentry L, Bresnick G, Boldt HC, Mieler WF, Tompkins D: Ferromagnetic hyperthermia: functional and histopathologic effects on normal rabbit ocular tissue. *Int J Hyperthermia* 13:423-436, 1997.
160. Mieler WF, Mittra RA: The role and timing of pars plana vitrectomy in penetrating ocular trauma (editorial). *Arch Ophthalmol* 113:1191-1192, 1997.
161. Macular Photocoagulation Study Group: Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Arch Ophthalmol* 115:741-747, 1997.
162. Grossniklaus HE, Albert DM, Green WR, Conway BP, Hovland KR, for the Collaborative Ocular Melanoma Study Group: Clear cell differentiation in choroidal melanoma. COMS Report No. 8. *Arch Ophthalmol* 115:894-898, 1997.
163. Mieler WF: Concurrent versus Sequential Application of Ferromagnetic Hyperthermia and 125-Iodine Brachytherapy of Melanoma in an Animal Model. *Trans Am Ophthalmol Soc XCV*:611-628, 1997.

164. Murray TG, Cicciarelli N, McCabe CM, Ksander B, Feuer W, Schiffman J, Mieler WF, O'Brien JM: In vitro efficacy of carboplatin and hyperthermia in a murine retinoblastoma cell line. *Invest Ophthalmol Vis Sci* 38:2516-2522, 1997.
165. Barza M, Pavan PR, Doft BH, Wisniewski SR, Wilson LA, Han DP, Kelsey SF, for the Endophthalmitis Vitrectomy Study Group: Evaluation of Microbiological Diagnostic Techniques in Postoperative Endophthalmitis in the Endophthalmitis Vitrectomy Study. *Arch Ophthalmol* 113:1142-1151, 1997.
166. Mieler WF: Microwave Thermoradiotherapy for Uveal Melanoma (discussion of manuscript). *Ophthalmol* 104:1803,1997.
167. Banker AS, Freeman WR, Kim JW, Munguia D, Azen SP, the Vitrectomy for Macular Hole Study Group: Vision-threatening complications of surgery for full- thickness macular holes. *Ophthalmol* 104:1442-1452, 1997.
168. Pollack JS, Mieler WF, Mittra RA: Golf-related ocular injuries. *Curr Opinion in Ophthalmol* 8:15-18, 1997.
169. The Collaborative Ocular Melanoma Study Group: Factors predictive of growth and treatment of small choroidal melanoma: COMS Report No. 5. *Arch Ophthalmol* 115:1537-1544, 1997.
170. The Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-enucleation Radiation of Large Choroidal Melanoma: I. Characteristics of Patients Enrolled and Not Enrolled. COMS Report No. 9. *Am J Ophthalmol* 125:767-778, 1998.
171. The Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-enucleation Radiation of Large Choroidal Melanoma: II. Initial Mortality Findings. COMS Report No. 10. *Am J Ophthalmol* 125:779-796, 1998.
172. The Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-enucleation Radiation of Large Choroidal Melanoma: III. Local Complications and Observations Following Enucleation. COMS Report No. 11. *Am J Ophthalmol* 126:362-372, 1998.
173. Doft BH, Kelsey SF, Wisniewski SR, the EVS Study Group: Additional Procedures after the Initial Vitrectomy or Tap-Biopsy in the Endophthalmitis Vitrectomy Study. *Ophthalmol* 105:707-716, 1998.
174. Collaborative Ocular Melanoma Study Group: Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6. *Am J Ophthalmol* 125:745-766, 1998.
175. Sperduto RD, Hiller R, Chew E, Seigel D, Blair N, Burton TC, Farber MD, Gragoudas ES, Haller J, Seddon JM, Yannuzzi LA: Risk factors for hemiretinal vein occlusion:

comparison with risk factors for central and branch retinal vein occlusion: The Eye Disease Case-Control Study. *Ophthalmol* 105:765-771, 1998.

176. Mittra RA, Huynh LT, Connor TB, Han DP, Mieler WF, Pulido JS, Ruttum MS, Dev S: Visual outcomes following lensectomy and vitrectomy for combined anterior and posterior persistent hyperplastic primary vitreous. *Arch Ophthalmol* 116:1190-1194, 1998.
177. Dev S, Mieler WF, Mittra RA, Prasad A: Acute macular edema associated with an infected scleral buckle. *Arch Ophthalmol* 116:1117-1119, 1998.
178. Han DP, Mohsin N, Guse CE, Hartz AJ, Tarkanian C, Wolf MD, Sramek SJ, Mieler WF, Pulido JS, Connor TB, and the Southeastern Wisconsin Pneumatic Retinopexy Study Group: Comparison of pneumatic retinopexy versus scleral buckling in the management of primary rhegmatogenous retinal detachment (RRD). *Am J Ophthalmol* 126:658-668, 1998.
179. Mittra RA, Connor TB, Han DP, Koenig SB, Mieler WF, Pulido JS: Management of dislocated intraocular lenses using pars plana vitrectomy with placement of an open-loop, flexible anterior chamber lens. *Ophthalmol* 105:1011-1014, 1998.
180. Mittra RA, Pollack JS, Mieler WF, Dev S, Han DP, Connor TB, Pulido JS: The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure (IOP) elevation following pars plana vitrectomy (PPV) with long-acting gas tamponade. *Trans Am Ophthalmol Soc XCVI*:143-154, 1998.
181. Pulido JS, Mieler WF, Walton D, Kuhn E, Postel EA, Hartz A, Jampol LM, Logani S, Weinberg D: Results of peripheral laser photocoagulation in pars planitis. *Trans Am Ophthalmol Soc XCVI*:127-142, 1998.
182. Wirostko WJ, Han DP, Mieler WF, Pulido JS, Connor TB, Kuhn E: Suprachoroidal hemorrhage: Outcome of surgical management according to hemorrhage severity. *Ophthalmol* 105: 2271-2275, 1998.
183. Mieler WF: Continuing Medical Education (CME) Credits (editorial). *Arch Ophthalmol* 117:247, 1999.
184. Chew EY, Sperduto RD, Hiller R, Nowroozi L, Seigel D, Yannuzzi LA, Burton TC, Seddon JM, Gradoudas ES, Haller JA, Blair NP, Farber M: Clinical course of macular holes: The Eye Disease Case-Control Study. *Arch Ophthalmol* 117:242-246, 1999.
185. Dev S, Pulido JS, Tessler HH, Mittra RA, Han DP, Mieler WF, Connor TB Jr: Progression of diabetic retinopathy after endophthalmitis. *Ophthalmol* 106:774-781, 1999.
186. Dev S, Mieler WF, Pulido JS, Mittra RA: Visual outcomes after pars plana vitrectomy for epiretinal membranes associated with pars planitis. *Ophthalmol* 106:1086-1090, 1999.

187. Cruickshanks KJ, Albert DM, Fryback D, Nondahl DM, Robinson N, Keesey U, Dalton DS, Robertson DM, Chandra SR, Mieler WF, Zakov ZN, Del Priore L, Custer PL: Effect of Treatment Choice on Quality of Life in Patients with Choroidal Melanoma. *Arch Ophthalmol* 117: 461-467, 1999.
188. Suh DW, Ruttum MS, Stuckenschneider BJ, Mieler WF: Ocular findings following bone marrow transplantation in pediatric population. *Ophthalmol* 106:1564-1570, 1999.
189. Chaudhry NA, Alfaro VD, Han DP, Mieler WF, Liggett PE: Preoperative use of tissue plasminogen activator in large submacular hemorrhage. *Ophthalmic Surg Lasers* 30:176-180, 1999.
190. Banker AS, Freeman WR, Azen SP, Lai MY, the Vitrectomy for Macular Hole Study Group: A Multicentered clinical study of serum as adjuvant therapy for surgical treatment of macular holes. *Arch Ophthalmol* 117:1499-1502, 1999.
191. Mitra RA, Mieler WF: Controversies in the management of open-globe injuries involving the posterior segment. *Surv Ophthalmol* 44:215-225, 1999.
192. Rhee P, Dev S, Mieler WF: The development of subretinal neovascularization associated with pregnancy. *Retina* 19:520-524, 1999.
193. Borrillo JL, Mitra RA, Dev S, Mieler WF, Pescinski S, Prasad A, Rao PK, Koenig SB: Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. *Trans Am Ophthalmol Soc XCVII*:435-449, 1999.
194. The Collaborative Ocular Melanoma Study Group: Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study (COMS). Report No. 12, Part I. *J Ophthalmic Nurs Tech* 18:143-149, 1999.
195. The Collaborative Ocular Melanoma Study Group: Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study (COMS). Report No. 12, Part II. *J Ophthalmic Nurs Tech* 18:219-232, 1999.
196. Wirostko WJ, Mieler WF, Levin DS, Law SK, Kalenak JW, Tribble JR, Connor TB Jr, Pulido JS, Han DP: Hypotony and retinal complications following aqueous humor shunt implantation: The 1999 Dohlman Lecture. *Intl Ophthalmol Clinics* 40:1-12, 2000.
197. Amin HI, McDonald HR, Han DP, Jaffe GJ, Johnson MW, Lewis H, Lopez PF, Mieler WF, Neuwirth J, Sternberg P Jr, Werner JC, Ai E, Johnson RN: Vitrectomy update for macular traction in ocular toxocariasis. *Retina* 20:80-85, 2000.

198. Mittra RA, Pollack JS, Mieler WF, Dev S, Han DP, Connor TB, Pulido JS: The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure (IOP) elevation following pars plana vitrectomy (PPV) with long-acting gas tamponade. *Ophthalmol* 107:588-592, 2000.
199. Mieler WF: Outcome of sulcus fixation of dislocated posterior chamber intraocular lenses using temporary externalization of the haptics (Discussion of manuscript). *Ophthalmol* 107:485, 2000
200. Wirostko WJ, Mittra RA, Rao PK, Borrillo JL, Dev S, Mieler WF: A combination light-pipe, soft-tipped suction, and infusion cannula instrument for macular translocation. *Am J Ophthalmol* 129:549-551, 2000.
201. McCabe CM, Flynn HW Jr, McLean WC, Brod RD, McDonald HR, Johnson MW, Williams GA, Mieler WF, Macroaneurysm Study Group: Non-surgical management of macular hemorrhage secondary to retinal artery macroaneurysms. *Arch Ophthalmol* 118:780-785, 2000.
202. Wisniewski SR, Capone A, Kelsey SF, Groer-Fitzgerald S, Lambert HM, Doft BH, for the Endophthalmitis Vitrectomy Study: Characteristics after cataract extraction or secondary lens implantation among patients screened for the Endophthalmitis Vitrectomy Study. *Ophthalmol* 107:1274-1282, 2000.
203. Mittra RA, Borrillo JL, Dev S, Mieler WF, Koenig SB: Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. *Arch Ophthalmol* 118:912-917, 2000.
204. Schwartz SG, McPherson AR, Mieler WF, Sessoms SL, Moake JL, Holz ER: Bilateral combined occlusion of the central retinal artery and vein secondary to thrombotic thrombocytopenic purpura. *Arch Ophthalmol* 118:1304-1305, 2000.
205. Doft BH, Kelsey SF, Wisniewski SR, The EVS Study Group: Retinal detachment in the Endophthalmitis Vitrectomy Study. *Arch Ophthalmol* 118:1661-1665, 2000.
206. McCabe CM, Flynn HW Jr, Shields CL, Shields JA, Regillo CD, McDonald HR, Berrocal MH, Gass JDM, Mieler WF: Juxtapapillary capillary hemangiomas: Clinical features and visual acuity outcomes. *Ophthalmol* 107: 2240-2248, 2000.
207. Horn EP, McDonald HR, Johnson RN, Ai E, Williams GA, Lewis JM, Rubsamen PE, Sternberg P Jr, Bhisitkul RB, Mieler WF: Soccer ball-related retinal injuries: A report of 13 cases. *Retina* 20:604-609, 2000.
208. Kazemi S, Wirostko WJ, Sinha S, Mieler WF, Koenig SB, Sheth BP: Combined pars plana lensectomy-vitrectomy with open-loop flexible anterior chamber intraocular lens (AC IOL) implantation for subluxated lenses. *Trans Am Ophthalmol Soc* XCVIII:247-254, 2000.

209. Cheng L, Freeman WR, Ozerdem U, Song MK, Azen SP: Prevalence, correlates, and natural history of epiretinal membranes surrounding idiopathic macular holes. Vitrectomy for Macular Hole Study Group. *Ophthalmol* 107:853-859, 2000.
210. Mieler WF: Outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion (Discussion of manuscript). *Ophthalmol* 108:375-376, 2001.
211. The Collaborative Ocular Melanoma Study Group: Sociodemographic and clinical predictors of participation in two randomized trials: findings from the Collaborative Ocular Melanoma Study. COMS report No. 7. *Control Clin Trials* 22:526-537, 2001.
212. Johnson RN, McDonald HR, Lewis H, Grand MG, Murray TG, Mieler WF, Johnson MW, Boldt HC, Olsen KR, Tornambe PE, Folk JC: Traumatic macular hole. Observations, pathogenesis, and results of vitrectomy surgery. *Ophthalmol* 108:853-857, 2001.
213. Doft BH, Wisniewski SR, Kelsey SF, Fitzgerald SG, and the Endophthalmitis Vitrectomy Study Group: Diabetes and Postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. *Arch Ophthalmol* 119:650-658, 2001.
214. The Collaborative Ocular Melanoma Study Group: Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study (CCOMS). Report No. 12, Part I. *J Ophthalmic Nurs Tech* 18:143-149, 1999.
215. The Collaborative Ocular Melanoma Study Group: Cause-specific mortality coding, methods in the Collaborative Ocular Melanoma Study. COMS report No. 14. *Control Clin Trials* 22:248-262, 2001.
216. Collaborative Ocular Melanoma Study Group: Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study. COMS Report No. 15. *Arch Ophthalmol* 119:670-676, 2001.
217. The Collaborative Ocular Melanoma Study Group: Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS report No. 16. *Ophthalmol* 108:348-366, 2001.
218. Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for choroidal melanoma: II. Characteristics of patients enrolled and not enrolled. COMS Report No. 17. *Arch Ophthalmol* 119:951-968, 2001.
219. Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of I-125 Brachytherapy for choroidal melanoma: III. Initial mortality findings. COMS Report No. 18. *Arch Ophthalmol* 119:969-984, 2001.
220. Seddon JM, Rosner B, Sperduto RD, Yannuzzi L, Haller JA, Blair NP, Willett W, and

the Eye Disease Case-Control Study Group: Dietary fat and risk of advanced age-related macular degeneration. *Arch Ophthalmol* (in press).

221. Sheth BP, Mieler WF: Ocular manifestations of pregnancy. *Curr Opin Ophthalmol* 12:455-463, 2001.
222. Schwartz SG, Holz ER, Mieler WF, Kuhl DP: Retained lens fragments in resident-performed cataract extractions. *J Contact Lens Assoc America* 28:44-47, 2002.
223. Mieler WF: Ocular injuries: Is it truly possible to further limit the occurrence rate? (editorial). *Arch Ophthalmol* 119:1712-1713, 2001.
224. Schwartz SG, Mieler WF, Holz ER, Esmali B, Ragsdale PS, Font RL: Intravitreal hemoglobin spherulosis: a rare complication of subretinal hemorrhage. *Arch Ophthalmol* 120:83-85, 2002.
225. Levin DS, Han DP, Dev S, Wirostko WJ, Mieler WF, Connor TB, George V, Eastwood D: Subtenon's depot corticosteroid injections in patient with a history of corticosteroid-induced intraocular pressure elevation. *Am J Ophthalmol* 133:196-202, 2002.
226. Verteporfin Roundtable 2000 and 2001 Participants: Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat chroidal neovascularization due to age-related macular degeneration and other causes. *Retina* 22:6-18, 2002.
227. Schwartz SG, Kuhl DP, McPherson AR, Holz ER, Mieler WF: Twenty-year follow-up for scleral buckling. *Arch Ophthalmol* 120:325-329, 2002.
228. The EyeTech Study Group: Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. *Retina* 22:143-152, 2002.
229. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF, for the American Academy of Ophthalmology: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. *Ophthalmol* 109:1377-1382, 2002.
230. Doft BH, Wisniewski SR, Kelsey SF, Groer-Fiitzgerald S: Endophthalmitis Vitrectomy Study Group: Diabetes and Postcataract Extraction Endophthalmitis. *Curr Opin Ophthalmol* 13:147-151, 2002.
231. Jones R, Gore E, Mieler W, Murray K, Gillin M, Albano K, Erickson B: Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects. *Int J Radiat Oncol Biol Phys* 15:989-995, 2002.
232. Schwartz SG, Mieler WF: Medications and retinal toxicity. *Ophthalmol Clin North America* 15:517-528, 2002.

233. Doft BH, Wisniewski SR, Kelsey SF, Groer-Fitzgerald S; Endophthalmitis Vitrectomy Study Group: Diabetes and postcataract extraction endophthalmitis. *Curr Opin Ophthalmol* 13:147-151, 2002.
234. Hariprasad SM, Mieler WF, Holz ER: Vitreous penetration of orally administered gatifloxacin in humans. *Tran Am Ophthalmol Soc* XCX:153-159, 2002.
235. Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, Diddie DR, Engstrom RE Jr, Finger PT, Hovland KR, Joffe L, Olsen KR, Wells CG: The COMS randomized trial of Iodine-125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. *Ophthalmol* 109:2197-2206, 2002.
236. Eyetech Study Group: Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. *Retina* 11:143-152, 2002.
237. Hariprasad SM, Mieler WF, Holz ER: Vitreous and aqueous penetration of orally administered gatifloxacin in humans. *Arch Ophthalmol* 121:345-350, 2003.
238. Barrie T, Kreissig I, Heimann H, Holz ER, Mieler WF: Repair of a primary rhegmatogenous retinal detachment. *Br J Ophthalmol* 87:782, 2003
239. Holz ER, Mieler WF: View 3: The case for pneumatic retinopexy. *Br J Ophthalmol* 87:782-790, 2003.
240. Eyetech Study Group: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. *Ophthalmol* 110:979-986, 2003.
241. Collaborative Ocular Melanoma Study Group: Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1007. Findings from patients evaluated at Collaborative Ocular Melanoma Study centers. COMS Report No. 20. *Arch Ophthalmol* 121:1156-1162, 2003.
242. Collaborative Ocular Melanoma Study Group: Comparison of clinical, echographic, and histologic measurements from eyes with medium-sized choroidal melanoma in the Collaborative Ocular Melanoma Study. COMS Report No. 21. *Arch Ophthalmol* 121:1163-1171, 2003.
243. Holz ER, Linares L, Mieler WF, Weinberg DV: Exudative complications following photodynamic therapy. *Arch Ophthalmol* 121:1649-1652, 2003.
244. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, Kaiser RS, Bakri SJ, Maturi RK, Belmont J, Beer PM, Murray TG, Quiroz H, Mieler WF: Acute

- endophthalmitis following intravitreal triamcinolone acetonide injection. *Am J Ophthalmol* 136:791-796, 2003.
245. Moon SJ, Park P, Mieler WF: Screening for chloroquine and hydroxychloroquine retinopathy. *Contemporary Ophthalmol* 2:20;1-6, 2003.
 246. Moon SJ, Mieler WF: Retinal complications of bone marrow and solid organ transplantation. *Curr Opin Ophthalmol* 14:433-442, 2003.
 247. The Anecortave Acetate Clinical Study Group: Anecortave Acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration. *Ophthalmol* 110:2372-2383, 2003.
 248. Hariprasad SM, Mieler WF, Holz ER: Vitreous and aqueous penetration of orally administered gatifloxacin in humans (response to Letter to Editor). *Arch Ophthalmol* 2003 (in press).
 249. Gao H, Pennesi M, Shah K, Qiao X, Hariprasad SM, Mieler WF, Wu SM, Holz ER: Safety of intravitreal voriconazole: Electroretinographic and histopathologic studies. *Trans Am Ophthalmol Soc* 101:183-189, 2003.
 250. Collaborative Ocular Melanoma Study Group: Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanomas in the collaborative ocular melanoma study: COMS report no.2. *Arch Ophthalmol* 121:1163-1171, 2003.
 251. Early Treatment for Retinopathy of Prematurity Cooperative Group: Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. *Arch Ophthalmol* 121:1684-1994, 2003.
 252. Collaborative Ocular Melanoma Study Group: Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS Report No. 22. *Ophthalmol* 111:966-976, 2004
 253. Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, Prince RA: Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. *Arch Ophthalmol* 122:42-47, 2004.
 254. Gao H, Pennesi M, Shah K, Qiao X, Hariprasad SM, Mieler WF, Wu SM, Holz ER: Intravitreal voriconazole—Electroretinographic and histopathologic study. *Arch Ophthalmol* 122:1687-1692, 2004.
 255. Gao H, Qiao X, Gao R, Mieler WF, McPherson AR, Holz ER: Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina. *Vision Research* 44:349-356, 2004.

256. Augustin AJ, D'Amico DJ, Mieler WF, Schneebaum C, Beasley C: Safety of posterior juxtасleral depot administration of the angiostatic cortisone anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. *Graefe's Clin Ophthalmol* 243:9-12, 2004.
257. Dev S, Han DP, Mieler WF, Gonzalez-Vivas R, Pulido JS, Mittra RA, Connor TB: The role of dexamethasone as an adjunct in the management of postoperative bacterial endophthalmitis. *EVRS* 1:13-20, 2004.
258. Moshfeghi DM, Kaiser PK, Sears JE, Scott IU, Benz M, Murray TG, Sinesterra JP, Quiroz H, Kaiser RS, Belmont J, Bakri SJ, Beer PM, Maturi RK, Mieler WF: Vitreous wick syndrome-a potential cause of endophthalmitis after intravitreal injection of triamcinolone through the pars plana: Author Reply. *Am J Ophthalmol* 137:1160-1161, 2004.
259. VAM Study Writing Committee: Verteporfin therapy in age-related macular degeneration (VAM): An open-label multicenter photodynamic therapy study of 4435 patients. *Retina* 24:512-520, 2004.
260. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Green DL, Hawkins BS, Hayman J, Jaiyesimi I, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Thama J; Collaborative Ocular Melanoma Study Group Report 23. *J Clin Oncol* 22:2438-2344, 2004.
261. Phelps DL; ETROP Cooperative Group. The Early Treatment for Retinopathy of Prematurity study: better outcomes, changing strategy. *Pediatrics* 114:490-491, 2004.
262. Hardy RJ, Good WV, Dobson V, Palmer EA, Phelps DL, Quintos M, Tu B: Early Treatment for Retinopathy of Prematurity Cooperative Group. *Control Clin Trials* 25:311-325, 2004.
263. Schwartz SG, Mieler WF: Treatment options in the management of rhegmatogenous retinal detachment. *Comprehensive Ophthalmol Update* 5:285-294, 2004.
264. Hariprasad SM, Mieler WF, Shah GK, Blinder KJ, Apte RS, Holekamp NM, Thomas MA, Chi J, Prince RA: Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. *Trans Am Ophthalmol Soc* 102:149-157, 2004.
265. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer D, for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *NEJM* 351:2805-2816, 2004.
266. Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM, Grand

- MG, Thomas MA, Mieler WF, Chi J, Prince RA: Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. *Arch Ophthalmol* 123:39-44, 2005.
267. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG: Management of endogenous fungal endophthalmitis using voriconazole and caspofungin. *Am J Ophthalmol* 139:135-140, 2005.
268. Westfall AC, Osborne A, Kuhl D, Benz M, Mieler WF, Holz E: In-office intravitreal corticosteroids and acute endophthalmitis. *Arch Ophthalmol* 123:1075-1077, 2005.
269. Moshfeghi DM, Kaiser PK, Bakri SJ, Kaiser RS, Maturi RK, Sears JE, Scott IU, Belmont J, Beer PM, Quiroz H, Mieler WF: Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. *Ophthalmic Surg Laser Imaging* 36:24-29, 2005.
270. Iyer MN, Mieler WF, He F, Wensel T, Benz MS, Holz ER: Intravitreal clearance of moxifloxacin. *Trans Am Ophthalmol Soc* 103:76-81, 2005.
271. Chevez-Barríos P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C, Hurwitz MY, Hurwitz RL: Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. *J Clin Oncol* 23:7927-7935, 2005.
272. Goa H, Pennessi ME, Qiao X, Iyer MN, Wu SM, Holz ER, Mieler WF: Intravitreal moxifloxacin: Retinal safety study with electroretinography and histopathology. *Invest Ophthalmol Vis Sci* 47:1606-1611, 2006.
273. Hariprasad SM, Shah GK, Mieler WF, Feiner L, Blinder KJ, Holekamp NM, Gao H, Prince RA: Vitreous and aqueous penetration of orally administered moxifloxacin in humans. *Arch Ophthalmol* 124:178-182, 2006.
274. Iyer MN, He F, Wensel TG, Mieler WF, Benz MS, Holz ER: Clearance of intravitreal moxifloxacin. *Invest Ophthalmol Vis Sci* 47:317-319, 2006.
275. Seagle BL, Gasyna EM, Mieler WF, Norris JR Jr: Photoprotection of human retinal pigment epithelium cells against blue light-induced apoptosis by melanin free radicals from *Sepia officinalis*. *Proc Natl Acad Sci USA* 103:16644-16648, 2006.
276. Lee EW, Mieler WF: Ocular findings in a patient with hemophagocytic syndrome. *Arch Ophthalmol* 124:1656-1658, 2006.
277. Alexandrou TJ, Hariprasad SM, Benevento J, Rubin MP, Saidel M, Ksiazek S, Thompson K, Boonlayangoor S, Mieler WF: Reduction of preoperative conjunctival bacterial flora with the use of mupirocin nasal ointment. *Trans Am Ophthalmol Soc* 104:196-201, 2006.

278. Lee EW, Hariprasad SM, Mieler WF, Newman TL, Apte RS: Short term intraocular pressure trends after intravitreal triamcinolone injection. *Am J Ophthalmol* 143:365-367, 2007.
279. Kaiser PK, Goldberg MF, Davis AA, and the Anecortave Acetate Clinical Study Group: Posterior Juxtapapillary Depot Administration of Anecortave Acetate. *Surv Ophthalmol* 52(S):62-69, 2007.
280. Regillo CD, D'Amico DJ, Mieler WF, Schneebaum C, Beasley CH, Sullins GT: Clinical Safety Profile of Posterior Juxtapapillary Depot Administration of Anecortave Acetate 15 mg Suspension as Primary Therapy or Adjunctive Therapy with Photodynamic Therapy for Treatment of Wet Age-related Macular Degeneration. *Surv Ophthalmol* 52(S): 70-78, 2007.
281. Russell SR, Hudson HL, Jerdan JA, and the Anecortave Acetate Clinical Study Group: Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration; A Review of Clinical Outcomes. *Surv Ophthalmol* 52(S): 79-90, 2007.
282. Coffee RE, Westfall AC, Davis GH, Mieler WF, Holz ER: Symptomatic posterior vitreous detachment and the incidence of delayed retinal breaks: case series and meta-analysis. *Am J Ophthalmol* 144:409-413, 2007.
283. Samuel MA, Equi RA, Chang TS, Mieler WF, Jampol L, Hay D, Yannuzzi LA: Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVA): new observations and a proposed staging system. *Ophthalmol* 114:1526-1529, 2007.
284. Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, Van Gelder RN: Aqueous and vitreous concentration following topical administration of 1% voriconazole in humans. *Arch Ophthalmol* 126:18-22, 2008.
285. Hariprasad SM, Miller L, Mieler WF, Grassi M, Green JL, Jager RD: Vision-related quality of life in patients with diabetic macular edema. *Br J Ophthalmol* 92:89-92, 2008.
286. Mojica G, Hariprasad SM, Jager RD, Mieler WF: Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. *Br J Ophthalmol* 92:584, 2008.
287. Jager RD, Mieler WF, Miller JW: Age-Related Macular Degeneration (review). *N Engl J Med* 358:2606-2617, 2008.
288. Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Voriconazole in the treatment of fungal eye infections: a review of the current literature. *Br J Ophthalmol* 92:871-878, 2008.

289. Benevento JD, Jager RD, Noble AG, Latkany P, Mieler WF, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R; Toxoplasmosis Study Group: Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. *Arch Ophthalmol* 126:1152-1156, 2008.
290. Kiernan DF, Hariprasad SM, Chin E, Rago J, Mieler WF: Prospective comparison of fourier domain Cirrus optical coherence tomography versus time domain Stratus OCT for quantifying retinal thickness. *Am J Ophthalmol* (2008-in press).
291. Kang Derwent, JJ, Mieler WF: Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. *Trans Am Ophthalmol Soc* (2008-in press).
292. Gabrielian A, Hariprasad SM, Mieler WF, Grassi MA, Green JL, Jager RD: Assessing the impact of diabetic retinopathy on vision-related quality of life. *Graefe's Clin Exp Arch Ophthalmol* (submitted for publication).
293. Hariprasad SM, Mieler WF, Orengo-Nania S, Holz ER, Bell N, Gross RL: The use of oral gatifloxacin in the treatment of localized filtering bleb infections. *Current Eye Research* (submitted for publication).
294. Peracha MO, Benz MS, Mieler WF, Holz ER, Couvillion SS, Murray TG: Pars plana vitrectomy for complications of radiation retinopathy: Indications and results. *Arch Ophthalmol* (submitted for publication).
295. Drapala PW, Brey EM, Mieler WF, Venerus DC, Perez-Luna VH, Kang Derwent JJ: Synthesis and characterization of thermosensitive hydrogels crosslinked with poly(ethylene glycol) diacrylate for controlled protein release. *J Macromol* (submitted for publication).
296. Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF: Treatment of cystoid macular edema with the new-generation NSAID Nepafenac 0.1%. *Clin Ophthalmol* (submitted for publication).
297. Gabrielian A, Hariprasad SM, Mieler WF: Retinal artery occlusion associated with a patent foramen ovale. *Clin Ophthalmol* (submitted for publication).

Addendum #2

ABSTRACTS

1. Mieler WF, Blumenkranz M: Long-term follow-up of central retinal vein occlusion. *Invest Ophthalmol Vis Sci* 22(Suppl):69, 1982.
2. Aaberg TM, Mieler WF: Proliferative retinopathy. *Int Ophthalmol* 8:105, 1985.
3. Mieler WF, Shields JA, Augsburger JJ: Photocoagulation of small choroidal melanomas. *Graefe's Arch Clin Exp Ophthalmol* 1986.
4. Han DP, Lewis H, Williams GA, Mieler WF, Abrams GW: Laser photocoagulation in the acute retinal necrosis syndrome. *Invest Ophthalmol Vis Sci* 28(Suppl):9, 1987.
5. Scallon LJ, Mieler WF, Kies JC, Aaberg TM, Burke JM: Canthaxanthine retinopathy: An animal model. *Invest Ophthalmol Vis Sci* 28(Suppl):9, 1987.
6. Mieler WF, Chilbert M, Williams GA, Burke JM, Lambrou FH, Olsen K, Pellin MJ, Gruen D: Endoexcimer ablative photodecomposition of choroidal melanoma in a rabbit model. *Invest Ophthalmol Vis Sci* 28(Suppl):117, 1987.
7. Sternberg P, Han DP, Yeo JH, Barr CC, Lewis H, Williams GA, Mieler WF: Photocoagulation to prevent retinal detachment in acute retinal necrosis (ARN). *Ophthalmology* 94(Suppl):70, 1987.
8. Mieler WF, Will BR, Lewis H, Aaberg TM: Pars plana vitrectomy in the management of peripheral uveitis. *Ophthalmology* 94(Suppl):99, 1987.
9. Jaffe GJ, Mieler WF, Williams GA: Photoablation of ocular melanoma with a high powered argon endolaser. *Invest Ophthalmol Vis Sci* 29(Suppl):363, 1988.
10. Williams DF, Mieler WF, Jaffe GJ, Robertson DM: Magnetic resonance imaging of juxtapapillary radioactive plaques. *Invest Ophthalmol Vis Sci* 29(Suppl):364, 1988.
11. Markowitz JA, Diener-West M, Schachat AP, Fine SL, Straatsma BR, Earle JD, COMS Group: Baseline characteristics of the first 450 cases evaluated for the Collaborative Ocular Melanoma Study. *Invest Ophthalmol Vis Sci* 29(Suppl):120, 1988.
12. Steeves R, Paliwal B, Jaffe G, Mieler W, Brezovich I: Ferromagnetic thermotherapy, physics, and thermometry. *Proceedings of the International Society for Eye Research* 5:156, 1988.
13. Mieler WF, Jaffe G, Steeves R, Paliwal B, Brezovich I: Ferromagnetic hyperthermia and brachytherapy in the treatment of choroidal melanoma in rabbits. *Proceedings of the International Society for Eye Research* 5:166, 1988.
14. Williams DF, Williams GA, Abrams GW, Mieler WF, Aaberg TM, Hartz A.: The en bloc excision technique for diabetic traction retinal detachments. *Ophthalmology* 95(Suppl):124, 1988.
15. Lewis H, Abrams GW, Mieler WF, Williams GA, McDonald HR, Aaberg TM: Retroretinal membranes in proliferative vitreoretinopathy. *Ophthalmology* 95(Suppl):125, 1988.

16. Han DP, Lewis H, Lambrou FH, Mieler WF: Incidence and mechanisms of postvitrectomy glaucoma. *Ophthalmology* 95(Suppl):131, 1988.
17. Collaborative Ocular Melanoma Study Group: Second nonocular cancers in patients with choroidal melanoma. *Ophthalmology* 95(Suppl):128, 1988.
18. Williams DF, Mieler WF: Long-term follow-up of acute multifocal posterior placoid pigment epitheliopathy. *Ophthalmology* 95(Suppl):135, 1988.
19. Boone DC, Azen SP, Irvine A, and The Silicone Study Group: The validity and reliability of photographic documentation of proliferative vitreoretinopathy (PVR). *Controlled Clinical Trials* 9:275, 1988.
20. Mieler WF, Jaffe GJ, Williams DF, Steeves RA: Ferromagnetic thermotherapy in the treatment of choroidal melanoma in rabbits. *Invest Ophthalmol Vis Sci* 30(Suppl):8, 1989.
21. Han DP, Jaffe GJ, Schwartz DM, Lewis H, Abrams GW, Williams GA, Mieler WF, Hartz A: Risk factors for postvitrectomy fibrin formation. *Invest Ophthalmol Vis Sci* 30(Suppl):272, 1989.
22. Albert DM, Green WR, McLean IW, Smith ME, Zimmerman LE and the Collaborative Ocular Melanoma Study Group: Accuracy of diagnosis of choroidal melanoma in the collaborative ocular melanoma study. *Invest Ophthalmol Vis Sci* 30(Suppl):58, 1989.
23. Sneed SR, Pulido JS, Blodi LF, Clarkson JG, Flynn HF, Mieler WF: Surgical management of late onset retinal detachments associated with regressed retinopathy of prematurity. *Ophthalmology* (Suppl)96:91, 1989.
24. Boone DC, Lai M, Azen S, and The Silicone Study Group: Clinical judgement and centralized data management. *Controlled Clinical Trials* 10:339, 1989.
25. Mieler WF, Williams DF, Ellis MK, Han DP: Intraocular foreign bodies and endophthalmitis. *Invest Ophthalmol Vis Sci* 31(Suppl):20, 1990.
26. Murphy ML, Han DP, Mieler WF, Abrams GW, Lewis H: Outpatient fluid-air exchange soon after severe postvitrectomy diabetic vitreous hemorrhage: results, complications, and long-term follow-up. *Invest Ophthalmol Vis Sci* 31(Suppl):438, 1990.
27. Bennett SR, Williams DF, Abrams GW, Han DP, Mieler WF: Transient loss of light perception following vitreoretinal surgery. *Ophthalmology* 97(Suppl):130, 1990.
28. Mieler WF, Murray TG, Boldt HC, Zellmer D, Erickson B: Ytterbium-169: Experimental Evaluation of a new brachytherapy source. *Invest Ophthalmol Vis Sci* 32(Suppl):979, 1991.
29. Boldt HC, Murray TG, Steeves RA, Moros EG, Lewandowski M, Mieler WF: Combined ferromagnetic hyperthermia and Iodine-125 episcleral plaque therapy: Studies of therapeutic dose response curves. *Invest Ophthalmol Vis Sci* 32(Suppl):979, 1991.
30. Murray TG, Boldt HC, Gillin MT, Mieler WF: Sulfur-35 Endo-irradiation: Dosimetry modeling and experimental efficacy. *Invest Ophthalmol Vis Sci* 32(Suppl):979, 1991.
31. Abrams GW, Murray TG, Boldt HC, Han DP, Mieler WF: Tissue plasminogen activator (tPA): Determination of clinical limits of efficacy for intracameral delivery. *Invest Ophthalmol Vis Sci* 32(Suppl):1226, 1991.

32. Hyndiuk R, Murray TG, Palmer M, Boldt HC, Han DP, Mieler WF, Abrams GW: Perfluoro-n-octane: Evaluation of anterior segment toxicity associated with intraocular use. *Invest Ophthalmol Vis Sci* 32(Suppl):880, 1991.
33. Palay DA, Sternberg P, Davis J, Lewis H, Holland GP, Mieler WF, Jabs DA, Drews-Botsch C: Acyclovir decreases the risk of bilateral involvement in acute retinal necrosis. *Invest Ophthalmol Vis Sci* 32(Suppl):688, 1991.
34. Schachat AP, Dutton JJ, Nerad JA, Hawkins BS, COMS Study Group: Perioperative complications of enucleation surgery for choroidal melanoma. Report from the COMS. *Ophthalmology* 98:150, 1991.
35. Nichols CJ, Boldt HC, Mieler WF, Han DP, Olsen K: Ocular injuries caused by elastic cords. *Ophthalmol Digest* 4:8, 1991.
36. Mieler WF, Murray TG, Steeves RA, Moros EG, Boldt HC: Repetitive ferromagnetic hyperthermia (FMH) achieves enhanced tumoricidal activity. *Invest Ophthalmol Vis Sci* 33(Suppl):1254, 1992.
37. Thompson JT, Parver LM, Enger C, Mieler WF, Liggett PE, National Eye Trauma System: Endophthalmitis after penetrating ocular injuries with retained intraocular foreign bodies. *Invest Ophthalmol Vis Sci* 33(Suppl):746, 1992.
38. Hartz A, Han DP, Wang Q, Murray T, Boldt HC, Arrindell E, Jaffe GJ, Coe E, Mieler WF, Abrams GW, Lewis H, Gottlieb M: The association of postvitrectomy fibrin formation with long-term visual outcome. *Invest Ophthalmol Vis Sci* 33(Suppl):898, 1992.
39. Han DP, Murray TG, Boldt HC, Palmer M, Abrams GW, Mieler WF: Perfluoro-n-octane: Evaluation of acute anterior segment toxicity with intravitreal use. *Invest Ophthalmol Vis Sci* 33(Suppl):1313, 1992.
40. Murphy ML, Nanda SK, Mieler WF: Penetrating ocular injuries secondary to motor vehicle accidents. *Invest Ophthalmol Vis Sci* 33(Suppl):1312, 1992.
41. Dannenberg AL, Parver LM, Fowler C, National Eye Trauma System Investigators: Penetrating eye injuries related to assault: The National Eye Trauma System Registry. *Invest Ophthalmol Vis Sci* 33(Suppl):782, 1992.
42. Wolf MD, Mieler WF: Retinal detachment after cryotherapy for peripheral uveitis. *Ophthalmology* 99(Suppl): 1992.
43. Mieler WF, Suson J, Williams DF: Retained intraocular BB and shotgun foreign bodies. *Ophthalmology* 99(Suppl): 1992.
44. Stuckenschneider BJ, Mieler WF: Ocular findings following bone marrow transplantation. *Ophthalmology* 99(Suppl): 1992.
45. Murphy ML, Mieler WF, Lewandowski MF, Williams DF: Echographic pseudoextension of uveal melanoma. *Ophthalmology* 99(Suppl): 1992.
46. Piper JG, Han DP, Abrams GW, Mieler WF: Perioperative choroidal hemorrhage at pars plana vitrectomy: a case control study. *Ophthalmology* 99(Suppl):111-112, 1992.
47. Keithahn M, Bennett SR, Cameron D, Mieler WF: Retinal folds in Terson's syndrome. *Ophthalmology* 99(Suppl): 1992.

48. Thompson JT, Parver LM, Enger C, Mieler WF, Liggett PE: Infectious endophthalmitis after penetrating injuries with retained intraocular foreign bodies. *Ophthalmology* 99(Suppl): , 1992.
49. Mieler WF, Groessl S, Nanda SK: Penetrating ocular trauma secondary to assault. *Invest Ophthalmol Vis Sci* 34(Suppl):1117, 1993.
50. Rychwalski PJ, Han KP, Mieler WF, Abrams GW: Perfluoro-n-octane and relaxing retinotomies: risks, techniques, and visual outcome. *Invest Ophthalmol Vis Sci* 34(Suppl):992, 1993.
51. Liggett PE, Alfaro DV, Horio B, Chaudhry N, Mieler WF: Autologous serum as a tissue adhesive in the treatment of idiopathic macular holes. *Ophthalmology* 100(Suppl):73, 1993.
52. Han DP, Murphy ML, Mieler WF: A modified en bloc excision technique during vitrectomy for diabetic traction retinal detachment: results and complications. *Ophthalmology* 100(Suppl):88, 1993.
53. Nash RW, Pulido JS, Mieler WF, Han DP: A prototype semiconductor diode laser coagulator/cutter endoprobe. *Invest Ophthalmol Vis Sci* 35(Suppl):1261, 1994.
54. Liggett PE, Horio B, Skolik S, Alfaro DV, Christmas NJ, Saito Y, Mieler WF: Use of human autologous serum in vitrectomy for full thickness macular holes. *Invest Ophthalmol Vis Sci* 35(Suppl):1579, 1994.
55. Han DP, Pulido JS, Mieler WF: Vitrectomy for diabetic retinopathy and severe peripheral fibrovascular proliferation (PFP). *Invest Ophthalmol Vis Sci* 35(Suppl):1615, 1994.
56. Nanda SK, Mieler WF, Wolf MD: Golf-related ocular injuries. *Invest Ophthalmol Vis Sci* 35(Suppl):1699, 1994.
57. Filatov V, Chaudry NA, Skolik SA, Alfaro DF, Saito Y, Mieler WF, Liggett PE: Early vitrectomy and endolaser photocoagulation in insulin-dependent diabetics with severe vitreous hemorrhage. *Invest Ophthalmol Vis Sci* 35(Suppl):1750, 1994.
58. Wong ACL, Pulido JS, Barney NP, Mieler WF: Sterile endophthalmitis in rabbits caused by *Bacillus cereus* exotoxins. *Invest Ophthalmol Vis Sci* 35(Suppl):1911, 1994.
59. Park S, Mieler WF, Pulido JS: Peripheral laser scatter ablation in pars planitis. *Invest Ophthalmol Vis Sci* 35(Suppl):1981, 1994.
60. Liggett PE, Filatov V, Chaudhry N, Skolik ST, Alfaro DV, Mieler WF: Early vitrectomy and endolaser photocoagulation in Type I diabetics with severe vitreous hemorrhage. *Ophthalmology* 101(Suppl):86, 1994.
61. McDonald HR, Schatz H, Johnson RN, Abrams GW, Brown GC, Brucker AJ, Han DP, Mieler WF, Meyers S: Vitrectomy in eyes with peripheral retinal angiomas associated with traction macular detachment. *Ophthalmology* 101(Suppl):69, 1994.
62. Haimovici R, Gragoudas ES, Gregor ZJ, Mieler WF: Choroidal metastases from renal cell carcinoma. *Ophthalmology* 101(Suppl):110, 1994.
63. Blair JR, Mieler WF, Han DP, Pulido JS: Perfluorocarbon liquids as an adjuvant to vitrectomy in the management of severe diabetic traction detachment. *Invest Ophthalmol Vis Sci* 36(Suppl):441, 1995.

64. Mieler WF, Steeves R, Tomkins R, Nash RW, Blair JR, Gentry L, Paliwal B, Murray TG: Concurrent versus sequential ferromagnetic hyperthermia and Iodine-125 brachytherapy in the management of melanoma in an animal model. Invest Ophthalmol Vis Sci 36(Suppl):393, 1995.
65. Chang TS, Aylward GW, Davis JL, Gass JD, Mieler WF, Maberley AF, Oliver GL: Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis (IRVAN syndrome). Invest Ophthalmol Vis Sci 36(Suppl):620, 1995.
66. Law SK, Kalenal JW, Connor TB, Mieler WF, Pulido JS, Han DP: Retinal complications following glaucoma tube-shunt surgery. Ophthalmology 102(Suppl):172, 1995.
67. Mieler WF, Han DP, Pulido JS: Endophthalmitis Update. Invest Ophthalmol Vis Sci 37(Suppl):13, 1996.
68. Law SK, Kalenak JK, Connor TB, Pulido JS, Han DP, Mieler WF: Retinal Complications following Glaucoma Aqueous-Shunt Surgery. Invest Ophthalmol Vis Sci 37(Suppl):257, 1996.
69. Mieler WF, Chou F, Arrindell EL, Han DP, Pulido JS, Abrams GW: Perfluorocarbon Liquids in the Management of Complicated Vitreoretinal Conditions. Invest Ophthalmol Vis Sci 37(Suppl):397, 1996.
70. Chou F, Mieler WF, Han DP, Pulido JS: Results of Surgery for Giant Retinal Tears Pre- and Post-Perfluorocarbon Liquids. Invest Ophthalmol Vis Sci 37(Suppl):397, 1996.
71. Pieramici DJ, Aaberg TM, Capone A, deJuan E, Kuhn F, Meredith TA, Mieler WF, Olsen T, Rubsamen PE, Sternberg P, Stout T: System for Classifying Mechanical Injuries of the Eye. Invest Ophthalmol Vis Sci 37(Suppl):414, 1996.
72. Walton D, Postel EA, Pulido JS, Mieler WF, Logani SC, Jampol LM, Howe CA: Peripheral Scatter Photocoagulation in the Treatment of Pars Planitis. Invest Ophthalmol Vis Sci 37(Suppl):459, 1996.
73. Tayyanipour R, Kim JE, Mieler WF: Vitrectomy for Vitreous Hemorrhage associated with Choroidal Melanoma. Invest Ophthalmol Vis Sci 37(Suppl):620, 1996.
74. Kim JE, Mieler WF: Evaluation of Antibiotic Use in Penetrating Ocular Injury with Retained Intraocular Foreign Body. Invest Ophthalmol Vis Sci 37 (Suppl):701, 1996.
75. Loushin JP, Logani S, Pulido JS, Lampol LM, Mieler WF, Lewandowski MF: Clinical Manifestations and Echography of Pars Planitis. Invest Ophthalmol Vis Sci 37 (Suppl):784, 1996.
76. Tang WM, Pluido JS, Han DP, Mieler WF: HLA-DR2+ Intermediate Uveitis. Invest Ophthalmol Vis Sci 37 (Suppl):1038, 1996.
77. Postel EA, Heier J, Pulido JS, Waterhouse W, Han DP, Mieler WF: Long-Term follow-up of Iatrogenic Phototoxicity. Invest Ophthalmol Vis Sci 37 (Suppl):1150, 1996.
78. Steeves RA, Murray TG, Moros EG, Mieler WF, Paliwal BR: Simultaneous ferromagnetic hyperthermia and Iodine-125 brachytherapy for choroidal melanoma in rabbit. Radiation Research (in press)
79. Steeves RA, Murray TG, Tompkins DT, Nanda S, Paliwal BR, Mieler WF: Thermal enhancement with experimental choroidal melanoma: simultaneous vs. sequential

- hyperthermia and brachytherapy. Sixth International Congress on Hyperthermic Oncology (in press)
80. Steeves RA, Murray TG, Mieler WF: Repetitive versus single ferromagnetic hyperthermia treatments for choroidal melanomas in rabbits. American Association for Cancer Research (in press)
 81. Law SK, Kalenak JW, Tribel JK, Connor TB, Pulido JS, Han DP, Mieler WF: Postoperative hypotony and retinal complications following Ahmed glaucoma valve implantation. Invest Ophthalmol Vis Sci 38 (Suppl);12, 1997.
 82. Han DP, Mohsin N, Guse CE, Hartz AJ, Tarkanian C, Wolf MD, Sramek SJ, Mieler WF, Pulido JS, Connor TB, and the Southeastern Wisconsin Pneumatic Retinopexy Study Group: Comparison of pneumatic retinopexy versus scleral buckling in the management of primary rhegmatogenous retinal detachment (RRD). Invest Ophthalmol Vis Sci 38 (Suppl):483, 1997.
 83. Chaudry NA, Alfaro VA, Gonzalez C, Chen HH, Han DP, Mieler WF, Liggett PE: Preoperative use of tissue plasminogen activator (tPA) for surgical removal of submacular hemorrhage: Invest Ophthalmol Vis Sci 38 (Suppl):657, 1997.
 84. Mitra RA, Connor TB, Han DP, Mieler WF, Pulido JS: Management of dislocated posterior chamber intraocular lenses using pars plan vitrectomy combined with insertion of an anterior chamber lens: Invest Ophthalmol Vis Sci 38 (Suppl):667, 1997.
 85. Wirostko WJ, Han DP, Mieler WF, Pulido JS, Connor TB, hartz AJ, Guse CE: Suprachoroidal hemorrhage: A classification of severity and its association with visual and anatomic outcome. Invest Ophthalmol Vis Sci 38 (Suppl):670, 1997.
 86. Harrison SA, Schwartz SD, Mieler WF, Packer AJ, Liggett PE: Vitrectomy and autologous serum for the treatment of idiopathic macular hole. Invest Ophthalmol Vis Sci 38 (Suppl):736, 1997.
 87. McCabe CM, Mieler WF, Han DP, Pulido JS, Connor TB: Retinal detachment following macular hole surgery. Invest Ophthalmol Vis Sci 38 (Suppl):737, 1997.
 88. Mieler WF, Wirostko WJ, Kim JE, Groessl SA, Guse CE, and The Ocular Trauma Classification Group: A penetrating ocular trauma scoring system. Invest Ophthalmol Vis Sci 38 (Suppl):944, 1997.
 89. Landon RE, Wong VKW, Mieler WF: Penetrating ocular trauma secondary to athletic and recreational injuries. Invest Ophthalmol Vis Sci 38(Suppl):944, 1997.
 90. Kim: The National Eye Trauma Registry: Pediatric Eye Trauma.
 91. Mieler WF, Dev S, Pulido JS, Mitra RA: Visual Outcome after Pars Plana Vitrectomy for Epiretinal Membranes associated with Pars Planitis. Invest Ophthalmol Vis Sci 39 (Suppl): 641, 1998.
 92. McCabe CM, Flynn HW, and the Macroaneurysm Study Group: Non-Surgical Management of Submacular Hemorrhage Secondary to Retinal Artery Macroaneurysms. Invest Ophthalmol Vis Sci 39 (Suppl): 654, 1998.

93. Dev S, Pulido JS, Tessler HH, Mittra RA, Han DP, Connor TB, Mieler WF: Progression of Diabetic Retinopathy after Endophthalmitis. *Invest Ophthalmol Vis Sci* 39 (Suppl):674, 1998.
94. Mittra RA, Pollack JS, Dev S, Han DP, Mieler WF, Connor TB, Pulido JS: The Use of Topical Aqueous Suppressants in the Prevention of Postoperative Intraocular Pressure (IOP) Elevation following Pars Plana Vitrectomy (PPV) with Long-Acting Gas Tamponade. *Invest Ophthalmol Vis Sci* 39 (Suppl):376, 1998.
95. Suh DW, Stuckenschneider BJ, Ruttum M, Mieler WF: Ocular findings following bone marrow transplantation in pediatric population. *Ophthalmol* 1998.
96. Borrillo JI, Mittra RA, Dev S, Pescinski S, Rao PK, Mieler WF: Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. *Invest Ophthalmology Vis Sci* 40 (Suppl): 312, 1999.
97. Whitaker M, Dev S, Mieler WF, Wirostko WJ: Pars plana vitrectomy and inferior retinal laser in the management of pars planitis. *Invest Ophthalmol Vis Sci* 40 (suppl): 383, 1999.
98. Levin DS, Dev S, Wirostko WJ, Han DP, Mieler WF, Connor TB: Posterior subtenon corticosteroid injections (PST) in patients with a history of corticosteroid induced IOP elevation. *Invest Ophthalmol Vis Sci* 40 (suppl): 384, 1999.
99. Wirostko WJ, Mieler WF, Dev S: Peripheral combined hamartomas of the retina and retinal pigment epithelium. *Invest Ophthalmol Vis Sci* 40 (suppl): 766, 1999.
100. Borrillo JL, Dev S, Wirostko WJ, Connor TC, Mieler WF: Visual outcomes and complications after anterior chamber intraocular lens (AC IOL) placement in diabetic (DM) patients. *Invest Ophthalmol Vis Sci* 41 (suppl): 650, 2000.
101. Liggett PE, Quiroz-Meraco H, Alfaro V, Mieler W: Indocyanine green enhanced diode laser for the treatment of choroidal melanoma. *Invest Ophthalmol Vis Sci* 42 (suppl):220, 2001.
102. Schwartz SG, Kuhl DP, McPherson AR, Mieler WF, Holz ER: Long-term follow-up for loosening of encircling scleral buckling elements. *Invest Ophthalmol Vis Sci* 42 (suppl): 425, 2001.
103. Sun XK, Holz ER, Mieler WF, Barrow D, McPherson AR: Retinal vein occlusion occurring during coumadin therapy. *Invest Ophthalmol Vis Sci* 42 (suppl): 435, 2001.
104. SJ Moon, WF Mieler and ER Holz. Pilot Study of Intravitreal Injection of Triamcinolone Acetonide in Exudative Age-Related Macular Degeneration *Invest Ophthalmol Vis Sci* 43: 1220, 2002.
105. SM Hariprasad, WF Mieler, SG Schwartz, D Barrow, XK Sun, DP Nicolau and ER Holz. Vitreous Penetration of Orally Administered Gatifloxacin in Humans. *Invest Ophthalmol Vis Sci* 43: 4430, 2002.

106. XK Sun, WF Mieler, AR McPherson and ER Holz. Epiretinal Membrane Surgery in Patients Over 75 Years of Age. *Invest Ophthalmol Vis Sci* 43: 3504, 2002.
107. H Gao, X Qiao, WF Mieler, AR McPherson and ER Holz. Intravitreal Triamcinolone Does Not Change Vascular Endothelial Growth Factor (VEGF) mRNA Expression in Rat Retina. *Invest Ophthalmol Vis Sci* 43: 3918, 2002.
108. R Chandran, MA Worrall, R Sun, WF Mieler and ER Holz. Combined Lens-Sparing Vitrectomy and Scleral Buckling in Stage 4 Retinopathy of Prematurity with Significant Vitreoretinal Traction. *Invest Ophthalmol Vis Sci* 43: 4016, 2002.
109. R. Chandran, W.F. Mieler, A.R. McPherson¹ and E.R. Holz. Scleral Buckling in Stage 4 Retinopathy of Prematurity with Significant Vitreoretinal Traction. *Invest Ophthalmol Vis Sci* 44: 603, 2003.
110. H. Gao, M. Pennesi, K. Shah, W.F. Mieler, S.M. Wu and E.R. Holz. Safety of Intravitreal Voriconazole - Histopathologic and Electoretinographic Study. *Invest Ophthalmol Vis Sci* 44: 1860, 2003.
111. W.J. Wirostko, T.M. Aaberg, Jr., J.E. Kim, T. Chang, W.F. Mieler, M. Stur, D.A. Glaser and D.F. Martin. Photodynamic Therapy of Circumscribed Choroidal Hemangiomas. *Invest Ophthalmol Vis Sci* 44: 2156, 2003.
112. S.M. Hariprasad, W.F. Mieler, S. Orengo-Nania, E.R. Holz, N.P. Bell and R.L. Gross. Oral Gatifloxacin: A Novel Treatment Paradigm for the Management of Filtering Bleb Infection. *Invest Ophthalmol Vis Sci* 44: 2165, 2003.
113. P.W. Park, E. Mavrofrides, W.F. Mieler and E.R. Holz. Pilot Study of Intravitreal Injection of Triamcinolone Acetonide for Refractory Diabetic Macular Edema. *Invest Ophthalmol Vis Sci* 44: 3966, 2003.
114. G.H. Davis, C.B. Patel, W.F. Mieler and E.R. Holz. Correlation between Post-operative Visual Acuity and OCT 3 Findings after Macular Hole Surgery. *Invest Ophthalmol Vis Sci* 44: 3053, 2003.
115. Patel CB, Malinowski SM, Miller JA, Haimann MH, Weiss H, Mieler WF: West Nile Virus Choroiditis with Panuveitis. *Invest Ophthalmol Vis Sci* 44: 4314, 2003.
116. P. Chevez-Barrios, M. Chintagumpala, W. Mieler, E. Paysse, M. Boniuk, M.Y. Hurwitz and R.L. Hurwitz. Response of Retinoblastoma with Vitreous Seeds to Suicide Gene Therapy Using Adenoviral-mediated Delivery of Thymidine Kinase Followed by Ganciclovir. *Invest Ophthalmol Vis Sci* 45: 3360, 2004.
117. G.K. Shah, S.M. Hariprasad, S. Breit, W.F. Mieler, M.G. Grand and R. VanGelde. Treatment of Endogenous Fungal Endophthalmitis with Systemic and Intravitreal

- Voriconazole: A Clinical and Penetration Pharmacokinetic Study. Invest Ophthalmol Vis Sci 45: 4011, 2004.
118. G.H. Davis, W. Mieler, and E. Holz. Outcomes of Three Port Lens Sparing Vitrectomy for Stage 4A and 4B retinopathy of prematurity detachments. Invest Ophthalmol Vis Sci 45: 4060, 2004.
 119. M.O. Peracha, M.S. Benz, W.F. Mieler, E.R. Holz, T.G. Murray and S. Couvillion. Visual Outcomes following Pars Plan Vitrectomy for Complications of Radiation Retinopathy. Invest Ophthalmol Vis Sci 45: 1996, 2004.
 120. A.C. Westfall, A. Maa, W. Mieler and E. Holz. Incidence of Retinal Tears and Late-onset Retinal Breaks in Eyes with a Symptomatic Posterior Vitreous Detachment. Invest Ophthalmol Vis Sci 45: 2066, 2004.
 121. S.M. Hariprasad, K.J. Blinder, G.K. Shah, R.S. Apte, B. Rosenblatt, M.G. Grand, M.A. Thomas, N.M. Holekamp, W.F. Mieler and R.A. Princ. Determination of Vitreous and Aqueous Concentration of Topically Administered Moxifloxacin 0.5% in Humans. Invest Ophthalmol Vis Sci 45: 525, 2004.
 122. R.L. Font, K. Rishi, W.F. Mieler and P. Chevez-Barrios. Clinical, Cytological And Immunophenotypical Characteristics Of Primary Lymphoma Of Retina And Vitreous. An Analysis Of 20 Cases. Invest Ophthalmol Vis Sci 45: 1228, 2004.
 123. M.N. Iyer, F. He, T.G. Wensel, W.F. Mieler, M.S. Benz and E.R. Holz. Clearance of Intravitreal Moxifloxacin. Invest Ophthalmol Vis Sci 46: 3535, 2005.
 124. C.D. Regillo, D. D'Amico, W. Mieler, C. Beasley and Anecortave Acetate Clinical Study Group. Safety Outcomes of Clinical Studies for Anecortave Acetate in Patients With Exudative Age-Related Macular Degeneration (AMD). Invest Ophthalmol Vis Sci 46: 1373, 2005.
 125. W. Mieler and VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Safety Evaluation of Second Year Treatment of Age-Related Macular Degeneration With Pegaptanib Sodium (MacugenTM): VEGF Inhibition Study in Ocular Neovascularization (VISION). Invest Ophthalmol Vis Sci 46: 1380, 2005.
 126. H. Gao, M.E. Pennesi, M. Iyer, X. Qiao, E.R. Holz and W.F. Mieler. Safety of Intravitreal Moxifloxacin: Electroretinographic and Histopathologic Study. Invest Ophthalmol Vis Sci 46: 5553, 2005.
 127. P. Chevez-Barrios, A. Leen, S.J. Chai, M. Chintagumpala, W.F. Mieler, E. Paysse, K. Wilhelmus, M.Y. Hurwitz, C. Rooney and R.L. Hurwitz. Immune Response of Retinoblastoma Treated With Suicide Gene Therapy Using Adenoviral-Mediated Delivery of Thymidine Kinase Followed by Ganciclovir. Invest Ophthalmol Vis Sci 46: 5218, 2005.

128. K.A. Rezaei, E.M. Gasyna, L. Farrokh-Siar, W.F. Mieler, and K.A. Rezaei. The Effect of Blue Light on the Production of VEGF by Human Retinal Pigment Epithelial Cells. *Invest Ophthalmol Vis Sci* 46: 247, 2005.
129. E.M. Gasyna, K.A. Rezaei, W.F. Mieler, and K.A. Rezaei. Blue Light Induces Apoptosis in Human Fetal Retinal Pigment Epithelium. *Invest Ophthalmol Vis Sci* 46: 248, 2005.
130. K.A. Rezaei, E.M. Gasyna, K.A. Rezaei, and W.F. Mieler. AcrySof® Natural Filter Decreases the Blue Light Induced Apoptosis in Human Retinal Pigment Epithelium. *Invest Ophthalmol Vis Sci* 46: 249, 2005.
131. E.Lee, S.M. Hariprasad, W.F. Mieler. Short-Term Intraocular Pressure Trends After Intravitreal Triamcinolone Injection. *Invest Ophthalmol Vis Sci* 47: 348, 2006.
132. K.A. Rezaei, L.Farrokh-Siar, E.Gasyna, W.F. Mieler, K.A. Rezaei. The Correlation of Blue Light Induced Apoptosis and Vascular Endothelial Growth Factor Production in Human RPE Cells. *Invest Ophthalmol Vis Sci* 47: 1375, 2006.
133. T.J. Alexandrou, S.M. Hariprasad, W.F. Mieler, M.A. Saidel, S.Ksiazek, M.P. Rubin, J.Benevento, K.Thompson, S.Boonlayangoor. Elimination of Conjunctival Bacterial Flora With the Use of Mupirocin Nasal Ointment. *Invest Ophthalmol Vis Sci* 47: 1492, 2006.
134. Mieler WF: Advances in the Anti-Microbial Treatment of Endophthalmitis - Minisymposium
135. Mieler WF: New Methods of Antibiotic Delivery. *Invest Ophthalmol Vis Sci* 47: 1821, 2006.
136. S.Bazzaz, R.R. Lakhanpal, T.A. Albin, W.F. Mieler, M.S. Benz, E.R. Holz. Surgical Outcomes of Vitreomacular Traction Syndrome With and Without Indocyanine Green Assisted Internal Limiting Membrane Peeling. *Invest Ophthalmol Vis Sci* 47: 3243, 2006.
137. Gasyna EM, Rezaei KA, Rezaei, Mieler WF: Blue Light Induced Apoptosis in Human Fetal Retinal Pigment Epithelium Cells Depends on the Light Intensity and the Cultured Cells Age. *Invest Ophthalmol Vis Sci* 47: 348, 2006.
138. R.Coffee, A.C. Westfall, G.Davis, W.Mieler, E.R. Holz. Case Series and Meta-Analysis of Symptomatic Posterior Vitreous Separation and the Incidence of Delayed Retinal Breaks. *Invest Ophthalmol Vis Sci* 47: 4206, 2006.
139. J.C. Yeh, S.M. Hariprasad, J.Benevento, W.F. Mieler. Comparison of Efficacy Between Intravitreal and Pericocular Injection of Triamcinolone Acetonide for Refractory

- Pseudophakic Cystoid Macular Edema. *Invest Ophthalmol Vis Sci* 47: 4244, 2006.
140. J.D. Benevento, S.M. Hariprasad, W.F. Mieler. Visual Acuity Outcomes After Epiretinal Membrane Removal Using 25 Gauge Vitrectomy and Triamcinolone Acetonide Assisted Peeling of the Internal Limiting Membrane. *Invest Ophthalmol Vis Sci* 47: 4650, 2006.
 141. W.F. Mieler, The VERITAS Trial. VERITAS - The Rationale and Design of a Combination Therapy Trial For Wet AMD. *Invest Ophthalmol Vis Sci* 47: 5232, 2006.
 142. B.-L.L. Seagle, E.M. Gasyna, K.A. Rezaei, W.F. Mieler, J.R. Norris. Melanin Photoprotection in Human Retinal Pigment Epithelium Cells as Revealed by Time-Resolved Electron Paramagnetic Resonance Spectroscopy. *Invest Ophthalmol Vis Sci* 47: 5530, 2006.
 143. T.J. Alexandrou, S.M. Hariprasad, J.Benevento, W.F. Mieler. Reduction of Pre-Operative Conjunctival Bacterial Flora With the Use of Mupirocin Nasal Ointment. *Invest Ophthalmol Vis Sci* 48: 685, 2007.
 144. J.C. Chang, S.M. Hariprasad, J.Benevento, W.F. Mieler. Efficacy of 25-Gauge Vitrectomy, ILM Peeling, and Gas Fluid Exchange for Closing Chronic Macular Holes. *Invest Ophthalmol Vis Sci* 48: 2220, 2007.
 145. E.M. Gasyna, B.-L.L. Seagle, A.Wang, J.R. Norris, Jr., W.F. Mieler. Human Fetal Retinal Pigment Epithelium Cells Produce Melanin During Culturing. *Invest Ophthalmol Vis Sci* 48: 2519, 2007.
 146. V.Arun, T.Alexandrou, M.Saidel, S.Ksiasek, W.Mieler. Changes in Corneal Thickness After Cataract Extraction in Patients Over 75 Years Old, With Reference to Endothelial Cell Counts. *Invest Ophthalmol Vis Sci* 48: 3520, 2007.
 147. A.Wang, E.M. Gasyna, W.F. Mieler, J.R. Norris, Jr. Synthetic Melanin as a Photoprotector Against Radical Oxygen Species. *Invest Ophthalmol Vis Sci* 48: 5955, 2007.
 148. V.I. Johnson, S.M. Hariprasad, M.A. Grassi, J.Green, R.D. Jager, W.F. Mieler. The Impact of Diabetic Retinopathy on Vision-Related Quality of Life. *Invest Ophthalmol Vis Sci* 48: 164, 2007.
 149. G.J. Mojica, S.M. Hariprasad, C.Radhakrishnan, D.A. Mazzulla, W.F. Mieler. Short-Term Intraocular Pressure Trends Following Intravitreal Injection of Ranibizumab (Lucentis) for the Treatment of Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci* 48: 258, 2007.
 150. D.A. Mazzulla, S.M. Hariprasad, G.Mojica, C.Radhakrishnan, R.D. Jager, W.F. Mieler. Short-Term Intraocular Trends Following Intravitreal Injection of Bevacizumab

- (Avastin). *Invest Ophthalmol Vis Sci* 48: 263, 2007.
151. J.D. Benevento, T.J. Alexandrou, S.M. Hariprasad, A.Mazzulla, W.F. Mieler. Nasal Bacteria as a Source of Contamination During Intraocular Surgery. *Invest Ophthalmol Vis Sci* 48: 749, 2007.
 152. G.Belsare, S.Hariprasad, R.D. Jager, D.A. Mazzulla, W.Mieler. Effects on Visual Acuity and OCT Following Older Generation AMD Treatment With Subsequent Lucentis or Avastin Intravitreal Injections. *Invest Ophthalmol Vis Sci* 48: 1443, 2007.
 153. S.K. Kim, L.Espandar, J.E. Romaguera, W.F. Mieler. Bilateral Color Blindness and Retinopathy Associated With Denileukin Diftitox (Ontak) in Follicular Lymphoma Patients. *Invest Ophthalmol Vis Sci* 48: 3809, 2007.
 154. W.F. Mieler, II, InSight CNV Registry Oversight Committee. An Interim Analysis of the *InSight* CNV Registry: A Collaborative Initiative to Advance AMD Treatment.
 155. L.Miller, G.Mojica, S.M. Hariprasad, W.F. Mieler, M.Grassi, J.L. Green, R.D. Jager. Vision-Related Quality of Life in Patients With Diabetic Macular Edema. *Invest Ophthalmol Vis Sci* 48: 4994, 2007.
 156. D.F. Kiernan, S.M. Hariprasad, A.Praley, D.A. Mazzulla, W.F. Mieler. Intravitreally Injected Anti-VEGF Drugs Exert an Effect on Visual Acuity in the Fellow Eye. *Invest Ophthalmol Vis Sci* 48: 4938, 2007.
 157. J.C. Chang, D.F. Kiernan, S.M. Hariprasad, G. Belsare, A. Gabrielian, S. Patel, W.F. Mieler. Acquisition Time and Learning Curve Analysis of High-Definition CirrusTM Optical Coherence Tomography Compared to Standard-Resolution StratusTM OCT Among Ophthalmology Residents. *Invest Ophthalmol Vis Sci* 49: 937, 2008.
 158. T.J. Alexandrou, S.M. Hariprasad, W.F. Mieler. Pre-Operative Reduction of Nasal and Conjunctival Bacterial Fflora With the Use of Mupirocin Nasal Ointment: A Comparison of 3 vs. 5 Day Administration of Mupirocin. *Invest Ophthalmol Vis Sci* 49: 960, 2008.
 159. D.F. Kiernan, S.M. Hariprasad, J.A. Rago, R. Singh, E. Chin, W.F. Mieler. Prospective Comparison of High-Definition-CirrusTM Optical Coherence Tomography versus Standard-Resolution StratusTM OCT for Quantifying Central Macular Thickness. *Invest Ophthalmol Vis Sci* 49: 1174, 2008.
 160. B.K. Williams, Jr., D.F. Kiernan, R.D. Jager, R. Lin, W.F. Mieler. The Effect of Internal Limiting Membrane Peel During Epiretinal Membrane Removal on Visual Acuity and Recurrence Rate in Diabetic and Non-Diabetic Eyes. *Invest Ophthalmol Vis Sci* 49: 2054, 2008.
 161. K. Grant-Acquah, D.F. Kiernan, R.D. Jager, W.F. Mieler. Intraoperative Use of Kenalog for Epiretinal Membrane Removal Is Associated With Improved Visual Outcomes and Decreased Membrane Recurrence. *Invest Ophthalmol Vis Sci* 49:

2131, 2008.

162. R. Singh, A.P. Singh, A. Flaum, K. Grant-Acquah, D. Kiernan, N. James, W. Mieler, R.D. Jager. Comparative Transatlantic Survey of Patient Knowledge and Awareness of Hypertension and Its Effects on Eye Disease. *Invest Ophthalmol Vis Sci* 49: 2132, 2008.
163. J.J. Kang Derwent, A. Appel, K. Triandafilou, S. Benac, J. Moss, W.F. Mieler. Possible Role of Methylnaltrexone (MNTX) in Retinal Angiogenesis. *Invest Ophthalmol Vis Sci* 49: 3446, 2008.
164. E.M. Gasyana, Z.L. Gasyana, J.R. Norris, Jr., W.F. Mieler. Blue Light Induced Apoptosis in Human Fetal Retinal Pigment Epithelium Cells Depends on Free Radical Chemistry. *Invest Ophthalmol Vis Sci* 49: 3540, 2008.
165. Mieler WF, Drapala P, Benac S, Brey EM, Perez-Luna V, Kang Derwent JJ: Thermo-Responsive Hydrogel Drug Delivery System for the Posterior Segment of the Eye. *Invest Ophthalmol Vis Sci* 49: 3876, 2008.
166. Gabrielian A, Kiernan DF, Hariprasad SM, Lin T, Mieler WF: Effect of Intravitreal Bevacizumab for Retinal Disease on Injected and Fellow Eyes. *Invest Ophthalmol Vis Sci* 49: 4570, 2008.
167. Chin EK, Kiernan DF, Hariprasad SM, Singh R, Mieler WF: Superior Surgical Outcomes of 25- Over 20-Gauge Transconjunctival Vitrectomy Combined With Cataract Surgery for Vitreoretinal Diseases. *Invest Ophthalmol Vis Sci* 49: 4699, 2008.
168. Burrell GJ, Hariprasad SM, Mieler WF, Jager RD: Improvement in Visual Quality of Life After Traditional and Microincisional Vitrectomy Surgery. *Invest Ophthalmol Vis Sci* 49: 5970, 2008.

BOOK CHAPTERS

1. Stern WH, Lean JS, and The Silicone Study Group: Intraocular silicone oil versus gas in the management of proliferative vitreoretinopathy (PVR): A multicenter clinical study. In Freeman HM, Tolentino FI, eds., Proliferative Vitreoretinopathy. Springer-Verlag New York, Inc., New York, NY, 1989.
2. Murray TG, Mieler WF, Steeves RA: Ocular Ferromagnetic Hyperthermia. pp. 473-478. In Tumors of the Eye, Proceedings of The International Symposiums in Geneva, Switzerland, and Essen, West Germany. Kugler Publications (Netherlands/New York), 1991.
3. Mieler WF, Aaberg TM: Vitreous surgery in the management of peripheral uveitis. Developments in Ophthalmology. Volume 23. pp. 239-250 In Boke WRF, Manthey KF, Nussenblatt RB, eds., Intermediate Uveitis. S. Karger AG, Basel, Switzerland, 1992.
4. Mieler WF, Aaberg TM: Further observations on cryotherapy of the vitreous base in the management of peripheral uveitis. Developments in Ophthalmology. Volume 23. pp. 190-195 In Boke WRF, Manthey KF, Nussenblatt RB, eds., Intermediate Uveitis. S. Karger AG, Basel, Switzerland, 1992.
5. Boldt HC, Abrams GW, Murray TG, Han DP, Mieler WF: The Lowest Effective Dose of Tissue Plasminogen Activator for Fibrinolysis of Postvitrectomy Fibrin. pp. 353-357. In Stirpe M, ed., Advances in Vitreoretinal Surgery. Acta of the Third International Congress on Vitreoretinal Surgery. Ophthalmic Communications Society, Inc., New York, NY, 1992.
6. Blumenkranz MS, Ward T, Murphy S, Mieler W, Williams GA, Long J: Applications and Limitations of vitreoretinal Biopsy Techniques in Intraocular Large Cell Lymphoma. pp. 381-388. In Stirpe M, ed., Advances in Vitreoretinal Surgery. Acta of the Third International Congress on Vitreoretinal Surgery. Ophthalmic Communications Society, Inc., New York, NY, 1992.
7. Sneed SR, Pulido JS, Blodi CF, Clarkson JG, Flynn HW, Mieler WF: Surgical management of late-onset retinal detachments associated with regressed retinopathy of prematurity. In Flynn JT, Tasman W, eds., Retinopathy of Prematurity. A Clinician's Guide. Springer-Verlag, New York, NY, 1992.
8. Abrams GW, Arrindell EL, Wolf MD, Mieler WF, Han DP: Advances in Vitreous Surgery: Perfluorocarbon Liquids. pp. 237-248. In Franklin RM, ed., Retina and Vitreous. Proceedings of the New Orleans Academy of Ophthalmology 1992. Kugler Publications, New York, NY, 1993.
9. Collaborative Ocular Melanoma Study Group: Complications of enucleation surgery. COMS Report Number 2. pp. 181-190. In Franklin RM, ed., Retina and Vitreous. Proceedings of the New Orleans Academy of Ophthalmology 1992. Kugler Publications, New York, NY, 1993.
10. Murray TG, Mieler WF: Posterior Uveal Melanoma. pp. 382-292. In Margo CE, Hamed LM, Mames RN, eds., Diagnostic Problems in Clinical Ophthalmology. WB Saunders Co., Philadelphia, PA, 1994.

11. Mieler WF, Wolf MD: Management of Post-Vitrectomy Diabetic Vitreous Hemorrhage. pp. 330-340. In Lewis H, Ryan SJ, eds., Medical and Surgical Retina: Advances, Controversies, and Management. Mosby Year Book, St. Louis, MO, 1994.
12. Blair JR, Mieler WF: Retinal Toxicity Associated with Commonly Encountered Systemic Agents. In Lim JI, Sternberg P, eds., International Ophthalmology Clinics 35: 137-156, 1995.
13. Boldt HC, Mieler WF: Endophthalmitis. In Hyndiuk RA, Tabbara K, eds., Infections of the Eye, 2nd edition. Little, Brown and Co., Boston, MA, chapter 39, pp. 571-594, 1996.
14. Postel EA, Mieler WF: Posterior Segment Manifestations of Blunt Trauma. In Guyer DR, Yannuzzi LA, Chang S, Shields J, eds., Retina Vitreous Macula: A Comprehensive Text. W. B. Saunders Co., Philadelphia, PA, Chapter 69, pp. 831-843, 1999.
15. Postel EA, Mieler WF: Intraocular Foreign Bodies. In Guyer DR, Yannuzzi LA, Chang S, Shields J, eds., Retina Vitreous Macula: A Comprehensive Text. W. B. Saunders, Co., Philadelphia, PA, Chapter 118, pp. 1395-1406, 1999.
16. Kim JE, Mieler WF: Systemic Medications and Retinal Toxicity. In Guyer DR, Yannuzzi LA, Chang S, Shields J, eds., Retina Vitreous Macula: A Comprehensive Text. W. B. Saunders, Co., Philadelphia, PA, Chapter 71, pp. 855-872, 1999.
17. Mitra R, Mieler WF, Pollack JS: Retinal Arterial Macroaneurysms. In Yanoff M, Duker J, eds., Ophthalmology. Mosby Co., London, England, Chapter 8:26.1-4, 1999.
18. Postel EA, Mieler WF: Vitrectomy for Open-Globe Injuries. In Albert DM, ed., Ophthalmic Surgery: Principles and Techniques. Blackwell Science, Inc., Cambridge, MA, Chapter 47, pp. 615-641, 1999.
19. Tang W, Pulido JS, Mieler WF: Vitrectomy for Inflammatory Diseases. In Albert DM, ed., Ophthalmic Surgery: Principles and Techniques. Blackwell Science, Inc., Cambridge, MA, Chapter 50, pp. 663-681, 1999.
20. Mitra RA, Mieler WF: Drug and Light Ocular Toxicity. In Brown GC, Flynn HW Jr, Regillo C, eds., Essentials of Vitreoretinal Disease. Thieme Medical and Scientific Publishers, New York, NY, Chapter 34, pp. 545-558, 1999.
21. Mieler WF, Law SK, Kalenak JW, Tribble JR, Connor TB, Pulido JS, Han DP: Postoperative Hypotony and Retinal Complications following Ahmed Glaucoma Valve implantation. In Stirpe M, ed., Anterior and Posterior Segment Surgery: Mutual Problems and Common Interests. Acta of the Fifth International Congress on Vitreoretinal Surgery. Ophthalmic Communications Society, Inc., New York, NY, pp. 282-288, 1998
22. Wirostko WJ, Mieler WF, McCabe CM, Dieckert JP: Retained Intraocular Foreign Bodies. In Albert DM, Jakobiec FA, eds., Principles and Practice of Ophthalmology, 2nd Edition. W.B.Saunders, Co., Philadelphia, PA, Chapter 375, pp. 5241-5250, 1999.

23. Borillo L, Mieler WF, Vinger PF: Epidemiology and Prevention of Ocular Trauma. In Albert DM, Jakobiec FA., Principles and Practice of Ophthalmology, 2nd Edition. W.B.Saunders, Co, Philadelphia, PA, Chapter 377, pp. 5262-5266, 1999.
24. Mieler WF: Overview of Ocular Trauma. In Albert DM, Jakobiec FA, Principles and Practice of Ophthalmology, 2nd Edition. W.B. Saunders Co., Philadelphia, PA, Chapter 370, p 5179, 1999.
25. Kim SK, Christlieb R, Mieler WF, Jakobiec FA: Hypertension and Its Ocular Manifestations. In Albert DM, Jakobiec FA, eds., Principles and Practice of Ophthalmology, 2nd Edition, W. B. Saunders, Co., Philadelphia, PA, Chapter 323. pp. 4506-4524, 1999.
26. McCabe CM, Mieler WF, Postel EA: Intraocular Foreign Bodies. In Alfaro V, Liggett P, eds., Vitreoretinal Surgery of the Injured Eye. Lippincott-Raven Publishers, Philadelphia-New York, Chapter 22, pp. 257-272, 1999.
27. Chaudhry NA, Flynn HW Jr, Mieler WF: Ocular Trauma. In Parrish RK II, ed., Bascom Palmer Eye Institute's Atlas of Ophthalmology. Current Medicine. Philadelphia, PA , Chapter 45, pp. 313-324, 2000.
28. King L, Joshi JA, Wirostko, WJ, Mieler WF: Epiretinal Membranes. In Quiroz-Mercado H, Alfaro DV, Liggett PE, Tano Y, deJuan E Jr, eds., Macular Surgery, Chapter 14, 166-178, 2000.
29. Cardillo J, Quiroz-Mercado H, Mieler WF: Myopia. In Quiroz-Mercado H, Alfaro DV, Liggett PE, Tano Y, deJuan E Jr, eds., Macular Surgery, Chapter 34, pages 357-362, 2000.
30. Wirostko WJ, Mieler WF, McCabe CM: Intraocular Foreign Bodies. In Peyman GA, Meffert S, Conway MD, Chou F, eds., Vitreoretinal Surgical Techniques, Martin Dunitz Ltd, London, England, Chapter 40, pp. 443-456, 2001.
31. Mitra RA, Mieler WF: Systemic Therapeutic Agents and Retinal Toxicity. In Ryan SJ, ed., RETINA, 3rd Edition, CV Mosby-Year Book, Inc., St. Louis, MO, Chapter 111, pp. 1779-1796, 2001.
32. Mieler WF: Vitreous/Vitreoretinal Disorders. In Gold DH, Lewis RA, eds., Clinical Eye Atlas. AMA Press, Chicago, IL, pp. 779-866, 2002.
33. Kuhl D, Mieler WF: Ciliary Body. In Ocular Trauma: Principles and Practice. Kuhn F, Pieramici DJ, eds., Thieme New York, New York, Chapter 19, pp. 157-168, 2002.
34. Schwartz SG, Mieler WF: Management of Eyes with Perforating Injury. In Ocular Trauma: Principles and Practice. Kuhn F, Pieramici DJ, eds., Thieme New York, New York, Chapter 26, pp. 273-279, 2002.

35. Mieler WF: Preface. In Ocular Trauma and Emergencies: Medical and Surgical Management. Mieler WF, Hairston RJ, Parver LM, eds., American Academy of Ophthalmology, 2002-in press.
36. Hariprasad SM, Mieler WF: Trauma Epidemiology. In Ocular Trauma and Emergencies: Medical and Surgical Management. Mieler WF.
37. Moon SJ, Mieler WF, Contreras JE: Trauma Terminology and Classification. In Ocular Trauma and Emergencies: Medical and Surgical Management. Mieler WF, Hairston RJ, Parver LM, eds., American Academy of Ophthalmology, 2002-in press.
38. McCabe CM, Mieler WF, Postel EA: Intraocular Foreign Bodies. In Ocular Trauma and Emergencies: Medical and Surgical Management. Mieler WF, Hairston RJ, Parver LM, eds., American Academy of Ophthalmology, 2002-in press.
39. Mieler WF, Patel CB, Park PW: Intraoperative and Postoperative Complications of Retinal Detachment Repair in Myopes. In Proceeding of the VIth International Bietti Foundation, 2003-in press.
40. Gombos DS, Mieler WF: Therapy of Uveal Melanoma: Methods and Risk Factors Associated with Treatment. In Ocular Oncology, Marcel Dekker, Inc., New York, NY, Chapter 15, pp. 321-352, 2003.
41. Contreras JE, Mittra RA, Mieler WF, Pollack JS: Retinal Arterial Macroaneurysms. In Yanoff M, Duker J, eds., Ophthalmology, 2nd Edition. Harcourt Health Sciences, St. Louis, MO, Chapter 123, pp. 912-917, 2004.
42. Section 4: Retina and Vitreous Surgery. In Clinical Atlas of Procedures in Ophthalmic Surgery. Albert DM and Lucarelli MJ, eds., AMA Press, Chicago, IL, Section 4, pp. 121-186, 2004
43. Holz ER, Mieler WF: Pneumatic retinopexy. In Primary Retinal Detachment Options for Repair. Kreissig I, ed., Springer-Verlag, Heidelberg, Germany, Chapter 5, pp 55-80, 2004.
44. Hariprasad SM, Mieler WF: New Developments in the Treatment of Endophthalmitis. To the Macula and Beyond, In Proceedings of the 53rd annual New Orleans Academy of Ophthalmology. Kugler Publications, The Netherlands, pp. 123-132, 2005.
45. Schwartz SG, Mieler WF, Holz, ER: Treatment Options in the Management of Rhegmatogenous Retinal Detachment. ToThe Macula and Beyond, In Proceedings of the 53rd annual New Orleans Academy of Ophthalmology. Kugler Publications, The Netherlands, pp. 147-161, 2005.

46. Mittra RA, Mieler WF: Systemic Therapeutic Agents and Retinal Toxicity. In Ryan SJ, ed., RETINA, 4th Edition, CV Mosby-Year Book, Inc., St. Louis, MO, Section 7, Chapter 108, pp. 1839-1856, 2006.
47. Schwartz SG, McKeown CA, Mieler WF: Metabolic and Nutritional Abnormalities. In Retinal Imaging, Huang D, Kaiser PK, Lowder CY, Traboulsi EI, eds., Mosby Elsevier Publishing, Philadelphia, PA, Chapter 50, pp. 427-436, 2006.
48. Schwartz SG, Mieler WF: Medications and Retinal Toxicity. In Retinal Imaging, Huang D, Kaiser PK, Lowder CY, Traboulsi EI, eds., Mosby Elsevier Publishing, Philadelphia, PA, Chapter 51, pp. 437-447, 2006.
49. Hariprasad SM, Mieler WF: Evidence-Based Medicine and the Treatment of Endophthalmitis. In Evidence-Based Eye Care, Kertes PJ, Johnson TM, eds., Lippincott Williams & Wilkins. Chapter 10, pp. 224-234, 2007.
50. Kim SK, Mieler WF, Jakobiec FA, Rubin MP: Hypertension and Its Ocular Manifestations. In Albert DM, Jakobiec FA, eds., Principles and Practice of Ophthalmology, 3rd Edition, W. B. Saunders, Co., Philadelphia, PA, Chapter 320, pp. 4367-4384, 2008.
51. Lemley CA, Wirostko WJ, Mieler WF, McCabe CM, Dieckert JP: Intraocular Foreign Bodies. In Albert DM, Jakobiec FA, eds., Principles and Practice of Ophthalmology, 3rd Edition. W.B.Saunders, Co., Philadelphia, PA, Chapter 377, pp. 5137-5145, 2008.
52. Hariprasad SM, Borrillo L, Mieler WF: Epidemiology and Prevention of Ocular Trauma. In Albert DM, Jakobiec FA., Principles and Practice of Ophthalmology, 3rd Edition. W.B.Saunders, Co, Philadelphia, PA, Chapter 379, pp. 5159-5163, 2008.
53. Mieler WF, Hariprasad SM: Overview of Ocular Trauma. In Albert DM, Jakobiec FA, Principles and Practice of Ophthalmology, 3rd Edition. W.B. Saunders Co., Philadelphia, PA, Chapter 372, pp. 5071, 2008.
54. Rubin MP, Alexandrou TJ, Vinger PF, Mieler WF: Sports Injuries. In Albert DM, Jakobiec FA, Principles and Practice of Ophthalmology, 3rd Edition. W.B. Saunders Co., Philadelphia, PA, Chapter 378, pp. 5147-5158, 2008.
55. Mieler WF, Rubin M: Surgery for Open-Globe Injuries. In Retina and Vitreous Surgery: Surgical Techniques in Ophthalmology series. Bhavsar A, ed., Elsevier Publishing, 2008-in press.
56. Schwartz SG, Mieler WF: Retinal Angiography in Retinal Pharmacologic Retinal Toxicity. In Retinal Angiography and Optical Coherence Tomography. Arevalo JF, Ed., Springer Science, New York, NY (2009-in press).
57. Lin RC, Mieler WF: Surgery for Epiretinal Membranes. In Quiroz-Mercado H, Alfaro DV, Tano Y, Mieler WF, Kerrison J. Macular Surgery, 2nd Edition, Lippincott, 2009-in press.

58. Lin RC, Mieler WF: Systemic Medications and Retinal Toxicity. In Retinal Pharmacotherapy. Nguyen QK, Farah M, Rodriguez E, Mieler WF, eds., Elsevier Publishing, 2009-in press.
59. Kang Derwent JJ, Mieler WF: Drug Delivery: Thermoresponsive Hydrogels. In Retinal Pharmacotherapy. Nguyen QK, Farah M, Rodriguez E, Mieler WF, eds., Elsevier Publishing, 2009-in press.
60. Mieler WF: Drug Toxicities. In The Retinal Atlas, vol 2. Yannuzzi LA, Shields JA, Mieler WF. Mosby, St. Louis, MO (2009-in press).